Antibody formulation

ABSTRACT

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.

RELATED APPLICATION

This is a non-provisional application claiming priority under Section119(e) to provisional application 60/053,087, filed on Jun. 13, 1997,the contents of which are incorporated herein by reference.

FIELD OF THE INVENTION

This invention is directed to a stable aqueous pharmaceuticalformulation comprising an antibody.

BACKGROUND OF THE INVENTION

In the past ten years, advances in biotechnology have made it possibleto produce a variety of proteins for pharmaceutical applications usingrecombinant DNA techniques. Because proteins are larger and more complexthan traditional organic and inorganic drugs (i.e. possessing multiplefunctional groups in addition to complex three-dimensional structures),the formulation of such proteins poses special problems. For a proteinto remain biologically active, a formulation must preserve intact theconformational integrity of at least a core sequence of the protein'samino acids while at the same time protecting the protein's multplefunctional groups from degradation. Degradation pathways for proteinscan involve chemical instability (i.e. any process which involvesmodification of the protein by bond formation or cleavage resulting in anew chemical entity) or physical instability (i.e. changes in the higherorder structure of the protein). Chemical instability can result fromdeamidation, racemization, hydrolysis, oxidation, beta elimination ordisulfide exchange. Physical instability can result from denaturation,aggregation, precipitation or adsorption, for example. The three mostcommon protein degradation pathways are protein aggregation, deamidationand oxidation. Cleland et al Critical Reviews in Therapeutic DrugCarrier Systems 10(4): 307-377 (1993).

Included in the proteins used for pharmaceutical applications areantibodies. An example of an antibody useful for therapy is an antibodywhich binds to the CD18 antigen. CD18 is the common β subunit of threeheterodimeric membrane integrins restricted to leukocytes that mediatetrafficking and adhesion to the vascular endothelium, particularly atsites of inflammation (for reviews see Hynes, R. O. Cell, 69:11-25(1992); Stoolman, Cell, 56:907-910 (1989); Jutila et al. Transplantation48(5): 727-731 (1989); Springer, T. A., Nature 346:425-434 (1990); andAlbelda and Buck, FASEB J. 4:2868-2880 (1990)). The heterodimercontaining CD18 and CD11b (also called MAC-1) is found primarily onneutrophils, monocytes, and some lymphocytes whose normal interactionwith ICAM-1 on vascular endothelium mediates adhesion and “rolling” ofcells along the vasculature. In severe hemorrhagic trauma withconcurrent decrease in cardiac output and ischemia, early (within 30min) neutrophil activation (in response to released cytokines) andup-regulation of MAC-1 increases neutrophil “stickiness”. This precedesextravasation and release of proteases and superoxides that ultimatelylead to further tissue damage and increased vascular permeability(Hernandez et al, Am. J. Physiol., 253(3 Pt 2): H699-H703 (1987)).Reperfusion following resuscitation exacerbates the edema and necrosis,and leads to multi-organ failure and death. Early treatment withmonoclonal antibodies to CD18 in a partally-severed, ischemic rabbit eartrauma model alleviated tissue necrosis following reattachment (Vedderet al., J. Clin. Invest. 81:939-944 (1988)). A humanized antibody showedefficacy in reducing multi-organ damage and death in a rhesus monkeymodel of decreased cardiac output (created by depletion of ⅔ of bloodvolume for ˜2 hours (Mileski etal., Surgery, 108(2):206-212 (1990)).These studies point to the therapeutic potential of anti-CD18 antibodiesfor acute treatment of hemorrhagic shock.

Another antigen of interest for targeting with antibodies is the CD20antigen, also known as “Bp35”. CD20 is a human B cell marker which isexpressed during early pre-B cell development and remains until plasmacell differentiation. The CD20 molecule may regulate a step in theactivation process which is required for cell cycle initiation anddifferentiation and is usually expressed at very high levels onneoplastic B cells. Thus, the CD20 surface antigen can be targeted fortreating B cell lymphomas. U.S. Pat. No. 5,736,137 issued Apr. 7, 1998describes the chimeric antibody “C2B8” which binds the CD20 antigen andits use to treat B cell lymphoma.

There is a need in the art for a stable aqueous pharmaceuticalformulation comprising an antibody, such as an anti-CD18 or anti-CD20antibody, which is suitable for therapeutic use.

SUMMARY OF THE INVENTION

Accordingly, the invention provides a stable aqueous pharmaceuticalformulation comprising a therapeutically effective amount of an antibodynot subjected to prior lyophilizabon, a buffer maintaining the pH in therange from about 4.5 to about 6.0, a surfactant and a polyol. Preferablythe formulation is stable at a temperature of about 2-8° C. for at leastone year, and/or is stable at a temperature of about 30° C. for at leastone month and/or is stable following freezing and thawing of theformulation.

The invention also relates to an article of manufacture comprising acontainer holding a stable aqueous pharmaceutical formulation comprisinga therapeutically effective amount of an antibody not subjected to priorlyophilizabon, a buffer maintaining the pH in the range from about 4.5to about 6.0, a surfactant and a polyol.

In yet a further aspect, the invention relates to a method forstabilizing an antibody in an aqueous pharmaceutical formulation bycombining a therapeutically effective amount of an antibody notsubjected to prior lyophilization, a buffer maintaining the pH in therange from about 4.5 to about 6.0, a surfactant and a polyol.

In a still further aspect, the invention concerns a method of treating amammal comprising administering a therapeutically effective amount ofthe aqueous pharmaceutical formulation disclosed herein to a mammal,wherein the mammal has a disorder requiring treatment with the antibodyin the formulation. Where the antibody binds CD18, examples of disordersto be treated include hemorrhagic shock, thermal injury (such as thatresulting from burns), stroke (including ischemic and hemorrhagicstroke) and myocardial infarction. For an anti-IL8 antibody, disordersto be treated include inflammatory disorders such as adult respiratorydistress syndrome (ARDS), hypovolemic shock, ulcerative colitis, andrheumatoid arthritis. Where the antibody binds CD20, disorders to betreated include B cell lymphomas.

These and further aspects of the invention will be apparent to thoseskilled in the art.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B depict the amino acid sequence of rhuMAb CD18 heavychain (FIG. 1A; SEQ ID NO:1) and light chain (FIG. 1B; SEQ ID NO:2). Thesequence in italics in FIG. 1A (SEQ ID NO:3) is that of the leucinezipper.

FIGS. 2A and 2B are hydroflex plots of rhuMAb CD18 heavy chain (FIG. 2A)and light chain (FIG. 2B). Kyte-Dooliutle hydrophobicity calculationsaveraged with a window of 6 amino acids were made on the proteinsequence. Flexibility values were estimated from the product of thehydrophobicity of each residue and its side chain volume (again averagedover a window of 6 residues). Asn-Gly and Asn-Ser motifs in flexibleregions are more likely to deamidate than those in more rigidstructures. The CDRs are also shown. Most of the heavy chain methioninesand heavy chain Asn 84 are near the CDR's.

FIGS. 3A and 3B show the effect of storage temperature on lightscattering in different rhuMAb CD18 formulations after 5 weeks storageat the designated temperatures as measured by average absorbance in therange of 340-360 nm (FIG. 3A), or the ratio of A278 over A252 nm (FIG.3B). RhuMAb CD18 in formulation F3 is prone to the formation ofinsoluble aggregates.

FIG. 4 shows the effect of storage temperature on protein concentrationof rhuMAb CD18 formulations measured by absorbance at 278 nm correctedfor vehicle absorbance at 320 nm.

FIGS. 5A and 5B depict the effect of storage temperature on thestability of rhuMAb CD18 formulation F2 (FIG. 5A) and formulation F5(FIG. 5B) assayed by size exclusion chromatography (SEC). A smaller MWspecies (see arrows) appeared which was more pronounced at pH 6 (FIG.5B) compared to pH 5 (FIG. 5A).

FIGS. 6A and 6B represent the effect of storage time and temperature onthe stability of rhuMAb CD18 showing total peak area (FIG. 6A), and %main peak (FIG. 6B) for all formulations, assayed by SEC. No significantchange in total peak area was noted. F1 and F5 maintained the lowest %main peak.

FIG. 7 is an Arrhenius plot of the % main peak area from SEC of rhuMAbCD18 formulated in acetate with trehalose at pH 5 (F2). ActivationEnergy=19±6 kcal/mole.

FIG. 8 shows the effect of storage for 5 weeks at 40° C. on differentrhuMAb CD18 formulations, assayed by hydrophobic interactionchromatography (HIC). The early eluting peaks at 17.5 min and theshoulder at the leading edge of the main peak increased compared tocontrols at −70° C. F2 showed the least increase in both components (seeFIG. 9).

FIG. 9 shows the effect of storage for 5 weeks at different temperatureson formulation F2, assayed by HIC. A pre-main peak became apparentcompared to −70° C. control.

FIG. 10 depicts the effect of storage temperature on the stability ofrhuMAb CD18 (5 week data) assayed by HIC showing total peak arearecovered. A trend towards loss in area was noted in all formulationswith increasing storage temperatures, except for F5 which started lowerto begin with.

FIG. 11 shows the effect of storage for 5 weeks at differenttemperatures on formulation F2, assayed by reverse phase-hydrophobicliquid chromatography (RP-HPLC). A small partially resolved pre-mainpeak component (see arrow) increased at higher temperatures, while itsslightly earlier eluting neighbor remained unchanged.

FIG. 12 shows the effect of storage for 5 weeks on the stability ofrhuMAb CD18 assayed by RP-HPLC showing percentage of the main peak. F2and F3 showed the highest % main peak after 5 weeks at 40° C.

FIG. 13 is an Arrhenius plot based on the RP-HPLC % main peak forformulation F2. Activation energy (˜20 kcal/mole) was only approximatedfrom these data due to the very small K for 5° C., it appears similar tothat obtained with the SEC and ion-exchange HPLC (IEX) assays.

FIGS. 14A and 14B show the effect of storage temperature on thestability of rhuMAb CD18, assayed by IEX, on formulation F2 at pH 5(FIG. 14A) and F5 at pH 6 (FIG. 14B). Two pre-main peaks increased withincreasing time and temperature, more pronounced at pH 6. A hump from 22to 28 minutes is an artifact due to an impurity washing off the column.

FIG. 15 is an Arrhenius plot of the % main peak area from IEX of rhuMAbCDI8 formulated in acetate with trehalose at pH 5 (F2). ActivationEnergy=20±10 kcal/mole.

FIG. 16 shows the three dimensional structure of rhuMAb CD18, includingpositions of methionine residues. Met 65 and Met 83 are exposed, whereasothers are buried in the structure and are expected to be less labile tooxidation.

FIG. 17 shows fluorescence spectroscopy of rhuMAb CD18 formulations. Theemission spectra of various formulations were obtained on an SLM8000fluorimeter, using 280 nm excitation wavelength. 500 μL samples wereplaced in quartz cuveftes and spectra were obtained with a 2nm bandwidthat 22° C. Samples were prepared at the different pHs by dilution of aconcentrated stock to 0.1 mg/mL protein and analyses were made after 24hr at 25° C. The antibody is conformationally stable above pH 3.

FIGS. 18A and 18B depict the effect of pH and protein concentration onthe stability of rhuMAb CD18. Formulations in the pH range of 3 to 6 andconcentration range of 0.5 to 25 mg/mL were placed on stability at 40°C. and −70° C. for 2 months. Analyses were made by IEX (FIG. 18A) andSEC (FIG. 18B). pH 5 was found to be the preferred pH, irrespective ofprotein concentration.

FIGS. 19A, 19B and 19C depict the kinetics of degradation of rhuMAb CD18by SEC (FIG. 19A), IEX (FIG. 19B) and MAC-1 binding (FIG. 19C) atvarious temperatures. Duplicate samples in 10 mM Na acetate, 8%trehalose, 0.01% TWEEN 20™, pH 5 were prepared in 3 cc glass vials andplaced on stability at the indicated temperatures. In FIG. 19C, specificactivity was the ratio of MAC-1 binding to total F(ab′)₂ ELISA. Samplesare stable at 5° C. and 15° C. up to 43 weeks and at 30° C. up to 1month. Analyses were made at the time points indicated.

FIG. 20 depicts the structure of plasmid pS1130 used to produce rhuMAbCD18 of the example below.

FIGS. 21A and 21B depict the full nucleotide sequence (SEQ ID NO:9) andencoded amino acid sequences (SEQ ID No's:10 and 11, respectively) ofthe pS 1130 expression cassette.

FIG. 22 shows derivation of the 49A5 production cell line.

FIG. 23 is a schematic of the fermentation process for rhuMAb CD18.

FIGS. 24A and 24B depict the effect of pH on the rate of aggregation(FIG. 24A) and oxidation (FIG. 24B) of 40 mg/mL rhuMAb CD20, 25 mMhistidine, 0.02% polysorbate formulations at pH 5,6.5 or 7.5 stored at40° C.

FIG. 25 depicts the effect of excess molar ratios of trehalose on thefreeze-thaw induced aggregation of rhuMAb CD20 multidose formulations.Each formulation is composed of 40 mg/mL rhuMAb CD20, 20 mM acetate, 0to 1000:1 molar ratio of trehalose, 0.9% benzyl alcohol and 0.02%polysorbate 20, pH 5.0 The amount of trehalose in formulations 1-4 wasfollows: 1=0 moles trehalose: 1 mole of rhuMAb CD20 (0 mM trehalose);2=250 moles trehalose: 1 mole rhuMAb CD20 (67 mM trehalose); 3=500 molestrehalose: 1 mole rhuMAb CD20 (134 mM trehalose); and 4=1000 molestrehalose: 1 mole rhuMAb CD20 (267 mM trehalose).

FIG. 26 shows the effect of excess molar ratios of trehalose or sodiumchloride on the clarity of rhuMAb CD20 multdose formulations stored at40° C. for up to four weeks. The composition of the formulations is 40mg/mL rhuMAb CD20,20 mM acetate, 0 to 1000:1 molar ratio of trehalose orsodium chloride, 0.9% benzyl alcohol and 0.02% polysorbate 20 at pH 5.0.The clarity of the 500:1 and 1000:1 molar ratio of sodium chloride torhuMAb CD20 formulations was not measured after four weeks at 40° C. dueto the physical appearance of these formulations. The 500:1 ratioformulation was very opalescent while the 1000:1 ratio formulabon hadseparated into two phases composed of a thin opaque gel layer coveredwith an opalescent fluid. The O.D. of the 1000:1 molar ratio of sodiumchloride to rhuMAb CD20 formulation was 2.72 after two weeks storage at40° C.

FIG. 27 depicts the effect of excess molar ratios of trehalose on thestability of rhuMAb CD20 muffidose formulations stored at 40° C. asanalyzed by SEC HPLC. The composition of the formulations is 40 mg/mLrhuMAb CD20, 20 mM acetate, 0-267 mM trehalose, 0.9% benzyl alcohol and0.02% polysorbate 20 at pH 5.0. The amount of trehalose in formulations1-4 was as follows: 1=0 moles trehalose: 1 mole of rhuMAb CD20 (0 mMtrehalose); 2=250 moles trehalose: 1 mole rhuMAb CD20 (67 mM trehalose);3=500 moles trehalose: 1 mole rhuMAb CD20 (134 mM trehalose); and 4=1000moles trehalose: 1 mole rhuMAb CD20 (267 mM trehalose). The percentmonomer at each bmepoint was normalized to the percent monomer at T=0.

FIG. 28 shows the stability profile of the prototype liquid rhuMAb CD20multidose formulation stored at 2-8° C. for up to two years as measuredby SEC HPLC. The formulation was composed of 40 mg/mL rhuMAb CD20, 150mM trehalose, 0.9% benzyl alcohol and 0.02% polysorbate 20 at pH 5.0.The percent monomer at each timepoint was normalized to the percentmonomer at T=0. The bioactivity of the formulation stored at 2-8° C. fortwo years was 99.2% relative to the reference control as measured by theCDC assay.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS I. Definitions

The term “pharmaceutical formulation” refers to preparations which arein such form as to permit the biological actvity of the activeingredients to be unequivocally effective, and which contain noadditional components which are toxic to the subjects to which theformulation would be administered. “Pharmaceutically acceptable”excipients (vehicles, additives) are those which can reasonably beadministered to a subject mammal to provide an effective dose of theactive ingredient employed.

A “stable” formulation is one in which the protein therein essentiallyretains its physical stability and/or chemical stability and/orbiological activity upon storage. Various analytical techniques formeasuring protein stability are available in the art and are reviewed inPeptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., MarcelDekker, Inc., New York, N.Y., Pubs. (1991) and Jones, A. Adv. DrugDelivery Rev. 10: 29-90 (1993), for example. Stability can be measuredat a selected temperature for a selected time period. Preferably, theformulation is stable at room temperature (˜30° C.) or at 40° C. for atleast 1 month and/or stable at about 2-8° C. for at least 1 year for atleast 2 years. Furthermore, the formulation is preferably stablefollowing freezing (to, e.g., −70° C.) and thawing of the formulation.

A protein “retains its physical stability” in a pharmaceuticalformulation if it shows no signs of aggregation, precipitation and/ordenaturation upon visual examination of color and/or clarity, or asmeasured by UV light scattering or by size exclusion chromatography.

A protein “retains its chemical stability” in a pharmaceuticalformulation, if the chemical stability at a given time is such that theprotein is considered to still retain its biological activity as definedbelow. Chemical stability can be assessed by detecting and quantifyingchemically altered forms of the protein. Chemical alteration may involvesize modification (e.g. clipping) which can be evaluated using sizeexclusion chromatography, SDS-PAGE and/or matrix-assisted laserdesorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS),for example. Other types of chemical alteration include chargealteration (e.g. occurring as a result of deamidation) which can beevaluated by ion-exchange chromatography, for example.

An antibody “retains its biological activity” in a pharmaceuticalformulation, if the biological activity of the antibody at a given timeis within about 10% (within the errors of the assay) of the biologicalactivity exhibited at the time the pharmaceutical formulation wasprepared as determined in an antigen binding assay, for example. Other“biological activity” assays for antibodies are elaborated hereinbelow.

By “isotonic” is meant that the formulation of interest has essentiallythe same osmotic pressure as human blood. Isotonic formulations willgenerally have an osmotic pressure from about 250 to 350 mOsm.Isotonicity can be measured using a vapor pressure or ice-freezing typeosmometer, for example.

A “polyol” is a substance with multiple hydroxyl groups, and includessugars (reducing and nonreducing sugars), sugar alcohols and sugaracids. Preferred polyols herein have a molecular weight which is lessthan about 600 kD (e.g. in the range from about 120 to about 400 kD). A“reducing sugar” is one which contains a hemiacetal group that canreduce metal ions or react covalently with lysine and other amino groupsin proteins and a “nonreducing sugar” is one which does not have theseproperties of a reducing sugar. Examples of reducing sugars arefructose, mannose, maltose, lactose, arabinose, xylose, ribose,rhamnose, galactose and glucose. Nonreducing sugars include sucrose,trehalose, sorbose, melezitose and raffinose. Mannitol, xylitol,erythritol, threitol, sorbitol and glycerol are examples of sugaralcohols. As to sugar acids, these include L-gluconate and metallicsalts thereof. Where it desired that the formulation is freeze-thawstable, the polyol is preferably one which does not crystallize atfreezing temperatures (e.g. −20° C.) such that it destabilizes theantibody in the formulation. Nonreducing sugars such as sucrose andtrehalose are the preferred polyols herein, with trehalose beingpreferred over sucrose, because of the superior solution stability oftrehalose.

As used herein, “buffer” refers to a buffered solution that resistschanges in pH by the action of its acid-base conjugate components. Thebuffer of this invention has a pH in the range from about 4.5 to about6.0; preferably from about 4.8 to about 5.5; and most preferably has apH of about 5.0. Examples of buffers that will control the pH in thisrange include acetate (e.g. sodium acetate), succinate (such as sodiumsuccinate), gluconate, histidine, citrate and other organic acidbuffers. Where a freeze-thaw stable formulation is desired, the bufferis preferably not phosphate.

In a pharmacological sense, in the context of the present invention, a“therapeutically effective amount” of an antibody refers to an amounteffective in the prevention or treatment of a disorder for the treatmentof which the antibody is effective. A “disorder” is any condition thatwould benefit from treatment with the antibody. This includes chronicand acute disorders or diseases including those pathological conditionswhich predispose the mammal to the disorder in question.

A “preservative” is a compound which can be included in the formulationto essentially reduce bacterial action therein, thus facilitating theproduction of a multi-use formulation, for example. Examples ofpotential preservatives include octadecyldimethylbenzyl ammoniumchloride, hexamethonium chloride, benzalkonium chloride (a mixture ofalkylbenzyldimethylammonium chlorides in which the alkyl groups arelong-chain compounds), and benzethonium chloride. Other types ofpreservatives include aromatic alcohols such as phenol, butyl and benzylalcohol, alkyl parabens such as methyl or propyl paraben, catechol,resorcinol, cyclohexanol, 3-pentanol, and m-cresol. The most preferredpreservative herein is benzyl alcohol.

As used herein, the term “inflammatory disorders” refers to pathologicalstates resulting in inflammation, e.g. caused by influx of leukocytesand/or neutrophil chemotaxis. Inflammation may result from infectionwith pathogenic organisms and viruses and noninfectious means such astrauma or reperfusion following myocardial infarction or stroke, immuneresponse to foreign antigen and autoimmune responses. Examples ofinflammatory disorders include inflammatory skin diseases such aspsoriasis and dermatitis; responses associated with inflammatory boweldisease (such as Crohn's disease and ulcerative colitis); ischemicreperfusion; adult respiratory distress syndrome; meningitis;encephalitis; uvei.s; autoimmune diseases such as rheumatoid arthritis,Sjorgen's syndrome, vasculitis; diseases involving leukocyte diapedesis;central nervous system (CNS) inflammatory disorder; multiple organinjury syndrome secondary to septcaemia or trauma; alcoholic hepatitis;bacterial pneumonia; antigen-antibody complex mediated diseases;hypovolemic shock; glomerulonephritis; multiple sclerosis; Type Idiabetes melitis; acute and delayed hypersensitivity; graft vs. hostdisease; transplant rejection; reperfusion injury; endotoxic shock;disease states due to leukocyte dyscrasia and metastasis; asthma;pulmonary oxygen toxicity; inflammation of the lung, including pleurisy,alveolitis, vasculitis, pneumonia, chronic bronchitis, bronchiectasis,and cystic fibrosis; etc.

The term “antibody” is used in the broadest sense and specificallycovers monoclonal antibodies (including full length monoclonalantibodies), polyclonal antibodies, multispecific antibodies (e.g.,bispecific antibodies), and antibody fragments so long as they exhibitthe desired biological activity.

“Antibody fragments” comprise a portion of a full length antibody,generally the antigen binding or variable region thereof. Examples ofantibody fragments include Fab, Fab′, F(ab′)₂, and Fv fragments;diabodies; linear antibodies; single-chain antibody molecules; andmultispecific antibodies formed from antibody fragments.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies,i.e., the individual antibodies comprising the population are identicalexcept for possible naturally occurring mutations that may be present inminor amounts. Monoclonal antibodies are highly specific, being directedagainst a single antgenic site. Furthermore, in contrast to conventional(polyclonal) antibody preparations which typically include differentantibodies directed against different determinants (epitopes), eachmonoclonal antibody is directed against a single determinant on theantigen. The modifier “monoclonal” indicates the character of theantibody as being obtained from a substantially homogeneous populationof antibodies, and is notto be construed as requiring production of theantibody by any particular method. For example, the monoclonalantibodies to be used in accordance with the present invention may bemade by the hybridoma method first described by Kohler et al., Nature256:495 (1975), or may be made by recombinant DNA methods (see, e.g.,U.S. Pat. No. 4,816,567). The “monoclonal antibodies” may also beisolated from phage antibody libraries using the techniques described inClackson et al, Nature 352:624-628 (1991) and Marks et al., J. Mol.Biol. 222:581-597 (1991), for example.

The monoclonal antibodies herein specifically include “chimeric”antibodies (immunoglobulins) in which a portion of the heavy and/orlight chain is identical with or homologous to corresponding sequencesin antibodies derived from a particular species or belonging to aparticular antibody class or subclass, while the remainder of thechain(s) is identical with or homologous to corresponding sequences inantibodies derived from another species or belonging to another antibodyclass or subclass, as well as fragments of such antibodies, so long asthey exhibit the desired biological activity (U.S. Pat. No. 4,816,567;and Morrison et al., Proc. NatL. Acad Sci. USA 81:6851-6855 (1984)).

The term “hypervariable region” when used herein refers to the aminoacid residues of an antibody which are responsible for antigen-binding.The hypervariable region comprises amino acid residues from a“complementarity determining region” or “CDR” (i.e. residues 24-34 (L1),50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35(H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain;Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.Public Health Service, National Institutes of Health, Bethesda, Md.(1991)) and/or those residues from a “hypervariable loop”(i.e. residues26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chaiin variabledomain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chainvariable domain; Chothia Lesk J. Mol. Biol. 196:901-917 (1987)).“Framework” or “FR” residues are those variable domain residues otherthan the hypervariable region residues as herein defined. The CDR and FRresidues of the H52 antibody of the example below are identified inEigenbrot et al. Proteins: Structure, Function and Genetics 18:49-62(1994).

“Humanized” forms of non-human (e.g., murine) antibodies are chimericantibodies which contain minimal sequence derived from non-humanimmunoglobulin. For the most part, humanized antibodies are humanimmunoglobulins (recipient antibody) in which residues from ahypervariable region of the recipient are replaced by residues from ahypervariable region of a non-human species (donor antibody) such asmouse, rat, rabbit or nonhuman primate having the desired specificity,affinity, and capacity. In some instances, FR residues of the humanimmunoglobulin are replaced by corresponding non-human residues.Furthermore, humanized antibodies may comprise residues which are notfound in the recipient antibody or in the donor antibody. Thesemodifications are made to further refine antibody performance. Ingeneral, the humanized antibody will comprise substantially all of atleast one, and typically two, variable domains, in which all orsubstantially all of the hypervariable regions correspond to those of anon-human immunoglobulin and all or substantially all of the FR regionsare those of a human immunoglobulin sequence. The humanized antibodyoptionally also will comprise at least a portion of an immunoglobulinconstant region (Fc), typically that of a human immunoglobulin. Forfurther details, see Jones et al., Nature 321:522-525 (1986); Riechmannet al, Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol.2:593-596 (1992).

“Single-chain Fv” or “sFv” antibody fragments comprise the V_(H) andV_(L) domains of antibody, wherein these domains are present in a singlepolypeptide chain. Generally, the Fv polypeptide further comprises apolypeptide linker between the V_(H) and V_(L) domains which enables thesFv to form the desired structure for antigen binding. For a review ofsFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol.113,Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994).

The term “diabodies” refers to small antibody fragments with twoantigen-binding sites, which fragments comprise a heavy chain variabledomain (V_(H)) connected to a light chain variable domain (V_(L)) in thesame polypeptide chain (V_(H)-V_(L)). By using a linker that is tooshort to allow pairing between the two domains on the same chain, thedomains are forced to pair with the complementary domains of anotherchain and create two antigen-binding sites. Diabodies are described morefully in, for example, EP 404,097; WO 93/11161; and Hollinger et al,Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993).

The expression “linear antibodies” when used throughout this applicationrefers to the antibodies described in Zapata et al. Protein Eng.8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair oftandem Fd segments (V_(H)-C_(H)1-V_(H)-C_(H)1) which form a pair ofantigen binding regions. Linear antibodies can be bispecific ormonospecific.

The antibody which is formulated is preferably essentially pure anddesirably essentially homogeneous (i.e. free from contaminating proteinsetc). “Essentially pure” antibody means a composition comprising atleast about 90% by weight of the antibody, based on total weight of thecomposition, preferably at least about 95% by weight. “Essentiallyhomogeneous” antibody means a composition comprising at least about 99%by weight of antibody, based on total weight of the composition.

“Treatment” refers to both therapeutic treatment and prophylactic orpreventative measures. Those in need of treatment include those alreadywith the disorder as well as those in which the disorder is to beprevented.

“Mammal” for purposes of treatment refers to any animal classified as amammal, including humans, domestic and farm animals, and zoo, sports, orpet animals, such as dogs, horses, cats, cows, etc. Preferably, themammal is human.

II. Modes for Carrying Out the Invention

The invention herein relates to a stable aqueous formulation comprisingan antibody. The antibody in the formulation is prepared usingtechniques available in the art for generating antibodies, exemplarymethods of which are described in more detail in the following sections.

The antibody is directed against an antigen of interest. Preferably, theantigen is a biologically important polypeptde and administration of theantibody to a mammal suffering from a disorder can result in atherapeutic benefit in that mammal. However, antibodies directed againstnonpolypeptide antigens (such as tumor-associated glycolipid antigens;see U.S. Pat. No. 5,091,178) are also contemplated.

Where the antigen is a polypeptide, it may be a transmembrane molecule(e.g. receptor) or ligand such as a growth factor. Exemplary antigensinclude molecules such as renin; a growth hormone, including humangrowth hormone and bovine growth hormone; growth hormone releasingfactor; parathyroid hormone; thyroid stimulating hormone; lipoproteins;alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin;follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon;clotting factors such as factor VIIIC, factor IX, tssue factor, and vonWillebrands factor; anti-clotting factors such as Protein C; atrialnatriuretic factor; lung surfactant; a plasminogen activator, such asurokinase or human urine or tssue-type plasminogen activator (t-PA);bombesin; thrombin; hemopoietic growth factor; tumor necrosisfactor-alpha and -beta; enkephalinase; RANTES (regulated on activationnormally T-cell expressed and secreted); human macrophage inflammatoryprotein (MIP-1-alpha); a serum albumin such as human serum albumin;Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain;prorelaxin; mouse gonadotropin-associated peptide; a microbial protein,such as beta-lactamase; DNase; IgE; a cytotoxic T-lymphocyte associatedantigen (CTLA), such as CTLA-4; inhibin; activin; vascular endothelialgrowth factor (VEGF); receptors for hormones or growth factors; proteinA or D; rheumatoid factors; a neurotrophic factor such as bone-derivedneurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT4,NT-5, or NT-6), or a nerve growth factor such as NGF-β; platelet-derivedgrowth factor (PDGF); fibroblast growth factor such as aFGF and bFGF;epidermal growth factor (EGF); transforming growth factor (TGF) such asTGF-alpha and TGF-beta, including TGF-β1, TGF-β2, TGF-β3, TGF-β4, orTGF-β5; insulin-like growth factor-I and -II (IGF-I and IGF-II);des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor bindingproteins; CD proteins such as CD3, CD4, CD8, CD19 and CD20;erythropoietin; osteoinductive factors; immunotoxins; a bonemorphogenetic protein (BMP); an interferon such as interferon-alpha,-beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF,GM-CSF, and G-CSF; interleukins (ILs), e.g., IL-1 to IL-10; superoxidedismutase; T-cell receptors; surface membrane proteins; decayaccelerating factor; viral antigen such as, for example, a portion ofthe AIDS envelope; transport proteins; homing receptors; addressins;regulatory proteins; integrns such as CD11a, CD11b, CD11c, CD18, anICAM, VLA-4 and VCAM; a tumor associated antigen such as HER2, HER3 orHER4 receptor; and fragments of any of the above-listed polypeptides.

Preferred molecular targets for antibodies encompassed by the presentinvention include CD proteins such as CD3, CD4, CD8, CD19, CD20 andCD34; members of the ErbB receptor family such as the EGF receptor,HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-1,Mac1, p150,95, VLA-4, ICAM-1, VCAM and αv/β3 integrin including either αor β subunits thereof (e.g. anti-CD11a, anti-CD18or anti-CD11bantibodies); growth factors such as VEGF; an interleukin such as IL8;IgE; blood group antigens; flk2/flt3 receptor; obesity (OB) receptor;mpl receptor; CTLA-4; protein C etc.

The preferred antibody herein is one which binds to human CD18 andpreferably blocks (partially or completely) the ability of a cell (e.g.a neutrophil) expressing the CD18 subunit at its cell surface to bind toendothelium. Examples of anti-CD18 antibodies include MHM23 (Hildreth etal., Eur. J. Immunol. 13:202-208 (1983)); M18/2 (IgG_(2a); Sanches-Madrdet al, J. Exp. Med.158:586 (1983)); H52 (American Type CultureCollection (ATCC) Deposit HB 10160); Mas191c and IOT18 (Vermot Desrocheset al., Scand. J. Immunol. 33:277-286 (1991)); and NA-8 (WO 94/12214).The preferred antibody is one which binds to the CD18 epitope to whicheither MHM23 or H52 binds. In certain embodiments, the antibody may bindto a region in the extracellular domain of CD18 which associates withCD11b and the antibody may also dissociate α and β chains (e.g. theantibody may dissociate the CD11b and CD18 complex as is the case forthe MHM23 antibody).

Techniques for producing antibodies which can be formulated as disclosedherein will be elaborated below.

A. Antibody Preparation

(i) Antigen Preparation

Soluble antigens or fragments thereof, optionally conjugated to othermolecules, can be used as immunogens for generating antibodies. Fortransmembrane molecules, such as receptors, fragments of these (e.g. theextracellular domain of a receptor) can be used as the immunogen.Alternatively, cells expressing the transmembrane molecule can be usedas the immunogen. Such cells can be derived from a natural source (e.g.cancer cell lines) or may be cells which have been transformed byrecombinant techniques to express the transmembrane molecule. Otherantigens and forms thereof useful for preparing antibodies will beapparent to those in the art.

(ii) Polyclonal Antibodies

Polyclonal antibodies are preferably raised in animals by multiplesubcutaneous (sc) or intraperitoneal (ip) injections of the relevantantigen and an adjuvant. It may be useful to conjugate the relevantantigen to a protein that is immunogenic in the species to be immunized,e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, orsoybean trypsin inhibitor using a bifunctional or derivatizing agent,for example, maleimidobenzoyl sulfosuccinimide ester (conjugationthrough cysteine residues), N-hydroxysuccinimide (through lysineresidues), glutaraldehyde, succinic anhydride, SOCI₂, or R¹N=C=NR, whereR and R¹ are different alkyl groups.

Animals are immunized against the antigen, immunogenic conjugates, orderivatives by combining, e.g., 100 μg or 5 μg of the protein orconjugate (for rabbits or mice, respectively) with 3 volumes of Freund'scomplete adjuvant and injecting the solution intradermally at multiplesites. One month later the animals are boosted with ⅕ to {fraction(1/10)} the original amount of peptide or conjugate in Freund's completeadjuvant by subcutaneous injection at multiple sites. Seven to 14 dayslater the animals are bled and the serum is assayed for antibody titer.Animals are boosted until the titer plateaus. Preferably, the animal isboosted with the conjugate of the same antigen, but conjugated to adifferent protein and/or through a different cross-linking reagent.Conjugates also can be made in recombinant cell culture as proteinfusions. Also, aggregating agents such as alum are suitably used toenhance the immune response.

(iii) Monoclonal Antibodies

Monoclonal antibodies may be made using the hybridoma method firstdescribed by Kohler et al., Nature, 256:495 (1975), or may be made byrecombinant DNA methods (U.S. Pat. No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, suchas a hamster or macaque monkey, is immunized as hereinabove described toelicit lymphocytes that produce or are capable of producing antibodiesthat will specifically bind to the protein used for immunization.Alternatively, lymphocytes may be immunized in vitro. Lymphocytes thenare fused with myeloma cells using a suitable fusing agent, such aspolyethylene glycol, to form a hybridoma cell (Goding, MonoclonalAntibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitableculture medium that preferably contains one or more substances thatinhibit the growth or survival of the unfused, parental myeloma cells.For example, if the parental myeloma cells lack the enzyme hypoxanthineguanine phosphoribosyl transferase (HGPRT or HPRT), the culture mediumfor the hybridomas typically will include hypoxanthine, aminopterin, andthymidine (HAT medium), which substances prevent the growth ofHGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stablehigh-level production of antibody by the selected antibody-producingcells, and are sensitive to a medium such as HAT medium. Among these,preferred myeloma cell lines are murine myeloma lines, such as thosederived from MOPC-21 and MPC-11 mouse tumors available from the SalkInstitute Cell Distribution Center, San Diego, Calif. USA, and SP-2 orX63-Ag8-653 cells available from the American Type Culture Collection,Rockville, Md. USA. Human myeloma and mouse-human heteromyeloma celllines also have been described for the production of human monoclonalantibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al,Monoclonal Antibody Production Techniques and Applications, pp. 51-63(Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed forproduction of monoclonal antibodies directed against the antigen.Preferably, the binding specificity of monoclonal antibodies produced byhybridoma cells is determined by immunoprecipitation or by an in vitrobinding assay, such as radioimmunoassay (RIA) or enzyme-linkedimmunoabsorbent assay (ELISA).

After hybridoma cells are identified that produce antibodies of thedesired specificity, affinity, and/or activity, the clones may besubloned by limiting dilution procedures and grown by standard methods(Goding, MonoclonalAntibodies: Principles and Practice, pp.59-103(Academic Press, 1986)). Suitable culture media for this purposeinclude, for example, D-MEM or RPMI-1640 medium. In addition, thehybridoma cells may be grown in vivo as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitablyseparated from the culture medium, ascites fluid, or serum byconventional immunoglobulin purification procedures such as, forexample, protein A-Sepharose, hydroxylapatite chromatography, gelelectrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequencedusing conventional procedures (e.g., by using oligonucleotide probesthat are capable of binding specifically to genes encoding the heavy andlight chains of the monoclonal antibodies). The hybridoma cells serve asa preferred source of such DNA. Once isolated, the DNA may be placedinto expression vectors, which are then transfected into host cells suchas E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells,or myeloma cells that do not otherwise produce immunoglobulin protein,to obtain the synthesis of monoclonal antibodies in the recombinant hostcells. Recombinant production of antibodies will be described in moredetail below.

In a further embodiment, antibodies or antibody fragments can beisolated from antibody phage libraries generated using the techniquesdescribed in McCafferty et al., Nature, 348:552-554 (1990).

Clackson et al., Nature, 352:624-628 (1991) and Marks etal., J. Mol.Biol., 222:581-597 (1991) describe the isolation of murine and humanantibodies, respectively, using phage libraries. Subsequent publicationsdescribe the production of high affinity (nM range) human antibodies bychain shuffling (Marks et al., Bio/Technology, 10:779-783 (1992)), aswell as combinatorial infection and in vivo recombination as a strategyfor constructing very large phage libraries (Waterhouse etal., Nuc.Acids. Res., 21:2265-2266 (1993)). Thus, these techniques are viablealternatives to traditional monoclonal antibody hybridoma techniques forisolation of monoclonal antibodies.

The DNA also may be modified, for example, by substituting the codingsequence for human heavy- and light-chain constant domains in place ofthe homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, etal., Proc. Natl Acad. Sci. USA, 81:6851 (1984)), or by covalentlyjoining to the immunoglobulin coding sequence all or part of the codingsequence for a non-immunoglobulin polypeptide.

Typically such non-immunoglobulin polypeptides are substituted for theconstant domains of an antibody, or they are substituted for thevariable domains of one antigen-combining site of an antibody to createa chimeric bivalent antibody comprising one antigen-combining sitehaving specificity for an antigen and another antigen-combining sitehaving specificity for a different antigen.

(iv) Humanized and Human Antibodies

A humanized antibody has one or more amino acid residues introduced intoit from a source which is non-human. These non-human amino acid residuesare often referred to as “import” residues, which are typically takenfrom an “import” variable domain. Humanization can be essentiallyperformed following the method of Winter and co-workers (Jones et al.,Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327(1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), bysubstituting rodent CDRs or CDR sequences for the correspondingsequences of a human antibody. Accordingly, such “humanized” antibodiesare chimeric antibodies (U.S. Pat. No. 4,816,567) wherein substantiallyless than an intact human variable domain has been substituted by thecorresponding sequence from a non-human species. In practice, humanizedantibodies are typically human antibodies in which some CDR residues andpossibly some FR residues are substituted by residues from analogoussites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be usedin making the humanized antibodies is very important to reduceantigenicity. According to the so-called “best-fit” method, the sequenceof the variable domain of a rodent antibody is screened against theentire library of known human variable-domain sequences. The humansequence which is closest to that of the rodent is then accepted as thehuman framework (FR) for the humanized antibody (Sims et al., J.Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901(1987)). Another method uses a particular framework derived from theconsensus sequence of all human antibodies of a particular subgroup oflight or heavy chains. The same framework may be used for severaldifferent humanized antibodies (Carter et al., Proc. Natl. Acad Sci.USA, 89:4285 (1992); Presta et al., J. Immnol., 151:2623 (1993)).

It is further important that antibodies be humanized with retention ofhigh affinity for the antigen and other favorable biological properties.To achieve this goal, according to a preferred method, humanizedantibodies are prepared by a process of analysis of the parentalsequences and various conceptual humanized products usingthree-dimensional models of the parental and humanized sequences.Three-dimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, i.e., theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind its antigen. In this way, FR residues can beselected and combined from the recipient and import sequences so thatthe desired antibody characteristic, such as increased affinity for thetarget antigen(s), is achieved. In general, the CDR residues aredirectly and most substantially involved in influencing antigen binding.

Alternatively, it is now possible to produce transgenic animals (e.g.,mice) that are capable, upon immunization, of producing a fullrepertoire of human antibodies in the absence of endogenousimmunoglobulin production. For example, it has been described that thehomozygous deletion of the antibody heavy-chain joining region (J_(H))gene in chimeric and germ-line mutant mice results in completeinhibifion of endogenous antibody production. Transfer of the humangerm-line immunoglobulin gene array in such germ-line mutant mice willresult in the production of human antibodies upon antigen challenge.See, e.g., Jakobovits et al, Proc. Natl. Acad. Sci. USA, 90:2551 (1993);Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Yearin Immuno., 7:33 (1993); and Duchosal et al. Nature 355:258 (1992).Human antibodies can also be derived from phage-display libraries(Hoogenboom et al, J. Mol. Biol., 227:381 (1991); Marks et al, J. MoLBiol., 222:581-597 (1991); Vaughan et al. Nature Biotech 14:309 (1996)).

(v) Antibody Fragments

Various techniques have been developed for the production of antibodyfragments. Traditionally, these fragments were derived via proteolyticdigestion of intact antibodies (see, e.g., Morimoto et al., Journal ofBiochemical and Biophysical Methods 24:107-117 (1992) and Brennan etal., Science, 229:81 (1985)). However, these fragments can now beproduced directly by recombinant host cells. For example, the antibodyfragments can be isolated from the antibody phage libraries discussedabove. Alternatively, Fab′-SH fragments can be directly recovered fromE. coli and chemically coupled to form F(ab′)₂ fragments (Carter et al.,Bio/Technology 10:163-167 (1992)). In another embodiment as described inthe example below, the F(ab′)₂ is formed using the leucine zipper GCN4to promote assembly of the F(ab′)₂ molecule. According to anotherapproach, F(ab′)₂ fragments can be isolated directly from recombinanthost cell culture. Other techniques for the production of antibodyfragments will be apparent to the skilled practitioner. In otherembodiments, the antibody of choice is a single chain Fv fragment(scFv). See WO 93/16185.

(vi) Multispecific Antibodies

Multspecific antibodies have binding specificities for at least twodifferent epitopes, where the epitopes are usually from differentantigens. While such molecules normally will only bind two differentepitopes (i.e. bispecific antibodies, BsAbs), antibodies with additionalspecificities such as trispecific antibodies are encompassed by thisexpression when used herein. Examples of BsAbs include those with onearm directed against a tumor cell antigen and the other arm directedagainst a cytotoxic trigger molecule such as anti-FcγRI/anti-CD15,anti-p185^(HER2)/FcγRIII (CD16), anti-CD3/anti-malignant B-cell (1D10),anti-CD3/anti-p185^(HER2), anti-CD3/anti-p97, anti-CD3/anti-renal cellcarcinoma, anti-CD3/anti-OVCAR-3, anti-CD3/L-D1 (anti-colon carcinoma),anti-CD3/anti-melanocyte stimulating hormone analog, anti-EGFreceptor/anti-CD3, anti-CD3/anti-CAMA1, anti-CD3/anti-CD19,anti-CD3/MoV18, anti-neural cell ahesion molecule (NCAM)/anti-CD3,anti-folate binding protein (FBP)/anti-CD3, anti-pan carcinomaassociated antigen (AMOC-31)/anti-CD3; BsAbs with one arm which bindsspecifically to a tumor antigen and one arm which binds to a toxin suchas anti-saporin/anti-ld-1, anti-CD22/anti-saporin,anti-CD7/anti-saporin, anti-CD38/anti-saporin, anti-CEA/anti-ricin Achain, anti-interferon-α(IFN-α)/anti-hybridoma idiotype,anti-CEA/anti-vinca alkaloid; BsAbs for converting enzyme activatedprodrugs such as anti-CD30/anti-alkaline phosphatase (which catalyzesconversion of mitomycin phosphate prodrug to mitomycin alcohol); BsAbswhich can be used as fibrinolytic agents such as anti-fibrin/anti-tssueplasminogen activator (tPA), anti-flbrin/anti-urokinase-type plasminogenactivator (uPA); BsAbs for targeting immune complexes to cell surfacereceptors such as anti-low density lipoprotein (LDL)/anti-Fc receptor(e.g. FcγRI, FcγRII or FcγRIII); BsAbs for use in therapy of infectiousdiseases such as anti-CD3/anti-herpes simplex virus (HSV), anti-T-cellreceptor:CD3 complex/anti-influenza, anti-FcyR/anti-HIV; BsAbs for tumordetection in vitro or in vivo such as anti-CEA/anti-EOTUBE,anti-CEA/anti-DPTA, anti-p185^(HER2)/anti-hapten; BsAbs as vaccineadjuvants; and BsAbs as diagnostic tools such as anti-rabbitIgG/anti-ferritin, anti-horse radish peroxidase (HRP)/anti-hormone,anti-somatostatin/anti-substance P, anti-HRP/anti-FITC,anti-CEA/anti-β-galactosidase. Examples of trispecific antibodiesinclude anti-CD3/anti-CD4/anti-CD37, anti-CD3/anti-CD5/anti-CD37 andanti-CD3/anti-CD8/anti-CD37. Bispecific antibodies can be prepared asfull length antibodies or antibody fragments (e.g. F(ab′)₂ bispecificantibodies).

Methods for making bispecific antibodies are known in the art.Traditonal production of full length bispecific antibodies is based onthe coexpression of two immunoglobulin heavy chain-light chain pairs,where the two chains have different specificities (Millstein et al.,Nature, 305:537-539 (1983)). Because of the random assortment ofimmunoglobulin heavy and light chains, these hybridomas (quadromas)produce a potential mixture of 10 different antibody molecules, of whichonly one has the correct bispecific structure. Purification of thecorrect molecule, which is usually done by affinity chromatographysteps, is rather cumbersome, and the product yields are low. Similarprocedures are disclosed in WO 93/08829, and in Traunecker et al., EMBOJ., 10:3655-3659 (1991).

According to a different approach, antibody variable domains with thedesired binding specificities (antibody-antigen combining sites) arefused to immunoglobulin constant domain sequences. The fusion preferablyis with an immunoglobulin heavy chain constant domain, comprising atleast part of the hinge, CH2, and CH3 regions. It is preferred to havethe first heavy-chain constant region (CH1) containing the sitenecessary for light chain binding, present in at least one of thefusions. DNAs encoding the immunoglobulin heavy chain fusions and, ifdesired, the immunoglobulin light chain, are inserted into separateexpression vectors, and are co-transfected into a suitable hostorganism. This provides for great flexibility in adjusting the mutualproportions of the three polypepbde fragments in embodiments whenunequal ratios of the three polypeptide chains used in the constructionprovide the optimum yields. It is, however, possible to insert thecoding sequences for two or all three polypeptide chains in oneexpression vector when the expression of at least two polypeptide chainsin equal ratios results in high yields or when the ratios are of noparticular significance.

In a preferred embodiment of this approach, the bispecific antibodiesare composed of a hybrid immunoglobulin heavy chain with a first bindingspecificity in one arm, and a hybrid immunoglobulin heavy chain-lightchain pair (providing a second binding specificity) in the other arm. Itwas found that this asymmetric structure facilitates the separation ofthe desired bispecific compound from unwanted immunoglobulin chaincombinations, as the presence of an immunoglobulin light chain in onlyone half of the bispecific molecule provides for a facile way ofseparation. This approach is disclosed in WO 94/04690. For furtherdetails of generating bispecific antibodies see, for example, Suresh etal., Methods in Enzymology, 121:210 (1986).

According to another approach described in WO96/27011, the interfacebetween a pair of antibody molecules can be engineered to maximize thepercentage of heterodimers which are recovered from recombinant cellculture. The preferred interface comprises at least a part of the C_(H)3domain of an antibody constant domain. In this method, one or more smallamino acid side chains from the interface of the first antibody moleculeare replaced with larger side chains (e.g. tyrosine or tryptophan).Compensatory “cavities” of identical or similar size to the large sidechain(s) are created on the interface of the second antibody molecule byreplacing large amino acid side chains with smaller ones (e.g. alanineor threonine). This provides a mechanism for increasing the yield of theheterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies include cross-linked or “heteroconjugate”antibodies. For example, one of the antibodies in the heteroconjugatecan be coupled to avidin, the other to biotin. Such antibodies have, forexample, been proposed to target immune system cells to unwanted cells(U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may bemade using any convenient cross-linking methods. Suitable cross-linkingagents are well known in the art, and are disclosed in U.S. Pat. No.4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragmentshave also been described in the literature. For example, bispecificantibodies can be prepared using chemical linkage. Brennan et al.,Science, 229: 81 (1985) describe a procedure wherein intact antibodiesare proteolytically cleaved to generate F(ab′)₂ fragments. Thesefragments are reduced in the presence of the dithiol complexing agentsodium arsenite to stabilize vicinal dithiols and prevent intermoleculardisulfide formation. The Fab′ fragments generated are then converted tothionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives isthen reconverted to the Fab′-thiol by reduction with mercaptoethylamineand is mixed with an equimolar amount of the other Fab′-TNB derivativeto form the bispecific antibody. The bispecific antibodies produced canbe used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab′-SH fragmentsfrom E. coli, which can be chemically coupled to form bispecificantibodies. Shalaby et al., J. Exp. Med., 175: 217-225 (1992) describethe production of a fully humanized bispecific antibody F(ab′)₂molecule. Each Fab′ fragment was separately secreted from E. coli andsubjected to directed chemical coupling in vitro to form the bispecificantibody.

Various techniques for making and isolating bispecific antibodyfragments directly from recombinant cell culture have also beendescribed. For example, bispecific antibodies have been produced usingleucine zippers. Kostelny et al., J. Immunol., 148(5):1547-1553 (1992).The leucine zipper pepbdes from the Fos and Jun proteins were linked tothe Fab′ portions of two different antibodies by gene fusion. Theantibody homodimers were reduced at the hinge region to form monomersand then re-oxidized to form the antibody heterodimers. This method canalso be utilized for the production of antibody homodimers. The“diabody” technology described by Hollinger et al., Proc. Nati. Acad.Sci. USA, 90:6444-6448 (1993) has provided an alternative mechanism formaking bispecific antibody fragments. The fragments comprise aheavy-chain variable domain (V_(H)) connected to a light-chain variabledomain (V_(L)) by a linker which is too short to allow pairing betweenthe two domains on the same chain. Accordingly, the V_(H) and V_(L)domains of one fragment are forced to pair with the complementary V_(L)and V_(H) domains of another fragment, thereby forming twoantigen-binding sites. Another strategy for making bispecific antibodyfragments by the use of single-chain Fv (sFv) dimers has also beenreported. See Gruber et al, J. Immunol, 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example,trispecific antibodies can be prepared. Tuft et al. J. Immunol. 147: 60(1991).

(vii) Effector Function Engineering

It may be desirable to modify the antibody of the invention with respectto effector function, so as to enhance the effectiveness of theantibody. For example cysteine residue(s) may be introduced in the Fcregion, thereby allowing interchain disulfide bond formation in thisregion. The homodimeric antibody thus generated may have improvedinternalization capability and/or increased complement-mediated cellkilling and antibody-dependent cellular cytotoxicity (ADCC). See Caronet al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol.148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumoractivity may also be prepared using heterobifunctonal cross-linkers asdescribed in Wolff et al. Cancer Research 53:2560-2565 (1993).Alternatively, an antibody can be engineered which has dual Fc regionsand may thereby have enhanced complement lysis and ADCC capabilities.See Stevenson et al Anti-Cancer Drug Design 3:219-230 (1989).

(viii) Antibody-Salvage Receptor Binding Epitope Fusions.

In certain embodiments of the invention, it may be desirable to use anantibody fragment, rather than an intact antibody, to increase tumorpenetration, for example. In this case, it may be desirable to modifythe antibody fragment in order to increase its serum half life. This maybe achieved, for example, by incorporation of a salvage receptor bindingepitope into the antibody fragment (e.g. by mutation of the appropriateregion in the antibody fragment or by incorporating the epitope into apeptide tag that is then fused to the antibody fragment at either end orin the middle, e.g., by DNA or peptide synthesis).

The salvage receptor binding epitope preferably constitutes a regionwherein any one or more amino acid residues from one or two loops of aFc domain are transferred to an analogous position of the antibodyfragment. Even more preferably, three or more residues from one or twoloops of the Fc domain are transferred. Still more preferred, theepitope is taken from the CH2 domain of the Fc region (e.g., of an IgG)and transferred to the CH1, CH3, or V_(H) region, or more than one suchregion, of the antibody. Alternatively, the epitope is taken from theCH2 domain of the Fc region and transferred to the C_(L) region or V_(L)region, or both, of the antibody fragment.

In one most preferred embodiment, the salvage receptor binding epitopecomprises the sequence (5′ to 3′): PKNSSMISNTP (SEQ ID NO:4), andoptionally further comprises a sequence selected from the groupconsisting of HQSLGTQ (SEQ ID NO:5), HQNLSDGK (SEQ ID NO:6), HQNISDGK(SEQ ID NO:7), or VISSHLGQ (SEQ ID NO:8), particularly where theantibody fragment is a Fab or F(ab′)₂. In another most preferredembodiment, the salvage receptor binding epitope is a polypeptidecontaining the sequence(s)(5′ to 3′): HQNLSDGK (SEQ ID NO:6), HQNISDGK(SEQ ID NO:7), or VISSHLGQ (SEQ ID NO:8) and the sequence: PKNSSMISNTP(SEQ ID NO:4).

(ix) Other Covalent Modifications of the Antibody

Covalent modifications of the antibody are included within the scope ofthis invention. They may be made by chemical synthesis or by enzymaticor chemical cleavage of the antibody, if applicable. Other types ofcovalent modifications of the antibody are introduced into the moleculeby reacting targeted amino acid residues of the antibody with an organicderivatizing agent that is capable of reacting with selected side chainsor the N- or C-terminal residues. Examples of covalent modifications aredescribed in U.S. Pat. No. 5,534,615, specifically incorporated hereinby reference. A preferred type of covalent modification of the antibodycomprises linking the antibody to one of a variety of nonproteinaceouspolymers, e.g., polyethylene glycol, polypropylene glycol, orpolyoxyalkylenes, in the manner set forth in U.S. Pat. Nos. 4,640,835;4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

(x) Selecting Biologically Active Antibodies

Antibodies produced as described above may be subjected to one or more“biological activity” assays to select an antibody with beneficialproperties from a therapeutic perspective.

The antibody may be screened for its ability to bind the antigen againstwhich it was raised. In the case of an anti-CD18 antibody, as shown inthe example below, the antigen binding properties of the antibody can beevaluated in a “MAC-1 capture assay”. Briefly, the assay involves firstcoating ELISA plates with an anti-CD18 antibody that binds to a site ofMAC-1 different from the anti-CD18 antibody of interest to capture arecombinant preparation of soluble MAC-1, followed by a wash, additionof the sample to be tested, wash, addition of goat HRP-labeledanti-human F(ab′)₂ antibody and colonmetric detection of OPD substrate.The total amount of antibody may be measured by first coating an ELISAplate with a polyclonal anti-F(ab′)₂ antibody, followed by addition ofthe sample, and then HRP-anti-F(ab′)₂ and colorimetric detection of theHRP substrate, OPD. Specific activity is the ratio of the MAC-1 bindingto total F(ab′)₂ ELISA value.

In another embodiment, the affinity of the antibody may be determined bysaturation binding; ELISA; and/or competition assays (e.g. RIA's), forexample.

Also, the antibody may be subjected to other biological activity assays,e.g., in order to evaluate its effectiveness as a therapeutic. Suchassays are known in the art and depend on the target antigen andintended use for the antibody.

Where the antibody binds CD18, examples of biological activity assaysinclude a slide adhesion assay, phagocytosis assay, neutrophil bindingassay and degranulation assay.

The slide adhesion assay involves preincubating heparinized blood withvarious concentrations of anti-CD18 antibody, and then placing aliquotsonto chambered glass slides. The slides are incubated at 37° C. to allowcells to adhere, nonadherent cells are gently washed off, the adherentcells are stained, and the average number of adherent cells permicroscope field is determined for 30 fields.

For the phagocytosis assay, heparinized whole blood is obtained and thered blood cells are lysed. The cells are then incubated with opsonizedBODIPY-labeled Staphylococcus aureus particles for 30 min at 37° C. Thecells are then analyzed by FACS, and the fluorescence intensity in theneutrophil gate is determined as an indication of the extent ofphagocytosis.

For determining binding of anti-CD18 antibody to neutrophils, wholeblood is incubated with various concentrations of the anti-CD18antibody. The cells are then stained with a FITC-conjugated goatanti-human F(ab′)₂ antibody, the red blood cells are lysed, and thewhite blood cells are analyzed by FACS. The fluorescence intensity inthe neutrophil gate is proportional to the extent of anti-CD18 antibodybinding.

For a degranulation assay, neutrophils are isolated from whole blood andpreincubated with anti-CD18 antibody. The cells are then stimulated withopsonized zymosan particles and allowed to stand at room temperature.The cellular supernatants are then collected, and degranulation isassessed either by specific ELISA (for myeloperoxidase or lactoferrin)or by enzyme assay (for elastase).

For other antibodies, examples of biological activity assays includetumor cell growth inhibition assays (as described in WO 89/06692, forexample); antibody-dependent cellular cytotoxicity (ADCC) andcomplement-mediated cytotoxicity (CDC) assays (U.S. Pat. No. 5,500,362);and agonistic activity or hematopoiesis assays (see WO 95/27062).

To screen for antibodies which bind to a particular epitope on theantigen of interest (e.g., those which block binding of the humanizedH52 antibody of the example to CD18), a routine cross-blocking assaysuch as that described in Antibodies, A Laboratory Manual, Cold SpringHarbor Laboratory, Ed Harlow and David Lane (1988), can be performed.Alternatively, epitope mapping, e.g. as described in Champe et al., J.Biol. Chem. 270:1388-1394 (1995), can be performed to determine whetherthe antibody binds an epitope of interest.

B. Vectors, Host Cells and Recombinant Methods

For recombinant production of the antibody, the nucleic acid encoding itis isolated and inserted into a replicable vector for further cloning(amplification of the DNA) or for expression. DNA encoding themonoclonal antibody is readily isolated and sequenced using conventionalprocedures (e.g., by using oligonucleotide probes that are capable ofbinding specifically to genes encoding the heavy and light chains of theantibody). Many vectors are available. The vector components generallyinclude, but are not limited to, one or more of the following: a signalsequence, an origin of replication, one or more marker genes, anenhancer element, a promoter, and a transcription termination sequence(e.g. as described in U.S. Pat. No. 5,534,615, specifically incorporatedherein by reference).

Suitable host cells for cloning or expressing the DNA in the vectorsherein are the prokaryote, yeast, or higher eukaryote cells describedabove. Suitable prokaryotes for this purpose include eubacteria, such asGram-negative or Gram-positive organisms, for example,Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter,Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium,Serrafia, e.g, Serratia marcescans, and Shigeila, as well as Bacillisuch as B. subtilis and B. licheniformis (e.g., B. licheniformis 41Pdisclosed in DD 266,710 published Apr. 12, 1989), Pseudomonas such as P.aeruginosa, and Streptomyces. One preferred E. coli cloning host is E.coli 294 (ATCC 31,446), although other strains such as E. coli B, E.coli X 1776 (ATCC 31,537), and E coil W3110 (ATCC 27,325) are suitable.These examples are illustrative rather than limiting.

In additlon to prokaryotes, eukaryotic microbes such as filamentousfungi or yeast are suitable cloning or expression hosts forantibody-encoding vectors. Saccharomyces cerevisiae, or common baker'syeast, is the most commonly used among lower eukaryotic hostmicroorganisms. However, a number of other genera, species, and strainsare commonly available and useful herein, such as Schizosaccharomycespombe; Kluyveromyces hosts such as, e.g., K. lactis, K. fragilis (ATCC12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K.waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans,and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070);Candida; Trichoderma reesia (EP 244,234); Neurospora crassa;Schwanniomyces such as Schwanniomyces occidentalis; and filamentousfungi such as, e.g., Neurospora, Penicillium, Tolypocladium, andAspergillus hosts such as A. nidulans and A. niger.

Suitable host cells for the expression of glycosylated antibody arederived from multicellular organisms. Examples of invertebrate cellsinclude plant and insect cells. Numerous baculoviral strains andvariants and corresponding permissive insect host cells from hosts suchas Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedesalbopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyxmori have been identified. A variety of viral strains for transfectionare publicly available, e.g., the L-1 variant of Autographa californicaNPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be usedas the virus herein according to the present invention, particularly fortransfection of Spodoptera frugiperda cells. Plant cell cultures ofcotton, corn, potato, soybean, petunia, tomato, and tobacco can also beutilized as hosts.

However, interest has been greatest in vertebrate cells, and propagationof vertebrate cells in culture (tissue culture) has become a routineprocedure. Examples of useful mammalian host cell lines are monkeykidney CV1 line transformed bySV40 (COS-7, ATCC CRL 1651); humanembryonic kidney line (293 or 293 cells subloned for growth insuspension culture, Graham et al, J. Gen Virol. 36:59 (1977)); babyhamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovarycells/-DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216(1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod. 23:243-251(1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkeykidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells(HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo ratliver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT060562, ATCC CCL51); TRI cells (Mather et al., Annals N.Y. Acad. Sci.383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line(Hep G2).

Host cells are transformed with the above-described expression orcloning vectors for antibody production and cultured in conventionalnutrient media modified as appropriate for inducing promoters, selectingtransformants, or amplifying the genes encoding the desired sequences.

The host cells used to produce the antibody of this invention may becultured in a variety of media. Commercially available media such asHam's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640(Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) aresuitable for culturing the host cells. In addition, any of the mediadescribed in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal.Biochem. 102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762;4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Pat. No. Re.30,985 may be used as culture media for the host cells. Any of thesemedia may be supplemented as necessary with hormones and/or other growthfactors (such as insulin, transferrin, or epidermal growth factor),salts (such as sodium chloride, calcium, magnesium, and phosphate),buffers (such as HEPES), nucleotides (such as adenosine and thymidine),antibiotics (such as GENTAMYCIN™drug), trace elements (defined asinorganic compounds usually present at final concentrations in themicromolar range), and glucose or an equivalent energy source. Any othernecessary supplements may also be included at appropriate concentrationsthat would be known to those skilled in the art. The culture conditions,such as temperature, pH, and the like, are those previously used withthe host cell selected for expression, and will be apparent to theordinarily skilled artisan.

When using recombinant techniques, the antibody can be producedintracellularly, in the periplasmic space, or directly secreted into themedium. If the antibody is produced intracellularly, as a first step,the particulate debris, either host cells or lysed cells, is removed,for example, by centrifugation or ultrafiltration. Where the antibody issecreted into the medium, supernatants from such expression systems aregenerally first concentrated using a commercially available proteinconcentration filter, for example, an Amicon or Millipore Pelliconultrafiltration unit. A protease inhibitor such as PMSF may be includedin any of the foregoing steps to inhibit proteolysis and antibiotics maybe included to prevent the growth of adventitious contaminants.

The antibody composition prepared from the cells can be purified using,for example, hydroxylapatite chromatography, gel electrophoresis,dialysis, and affinity chromatography, with affinity chromatographybeing the preferred purification technique. The suitability of protein Aas an affinity ligand depends on the species and isotype of anyimmunoglobulin Fc domain that is present in the antibody. Protein A canbe used to purify antibodies that are based on human γ1, γ2, or γ4 heavychains (Lindmark et al., J. Immunol. Meth. 62:1-13 (1983)). Protein G isrecommended for all mouse isotypes and for human γ3 (Guss et al., EMBOJ. 5:1567-1575 (1986)). The matrix to which the affinity ligand isattached is most often agarose, but other matrices are available.Mechanically stable matrices such as controlled pore glass orpoly(styrenedivinyl)benzene allow for faster flow rates and shorterprocessing times than can be achieved with agarose. Where the antibodycomprises a C_(H)3 domain, the Bakerbond ABX™resin (J. T. Baker,Phillipsburg, N.J.) is useful for purification. Other techniques forprotein purification such as fractionation on an ion-exchange column,ethanol precipitation, Reverse Phase HPLC, chromatography on silica,chromatography on heparin SEPHAROSET™ chromatography on an anion orcation exchange resin (such as a polyaspartic acid column),chromatofocusing, SDS-PAGE, and ammonium sulfate precipiation are alsoavailable depending on the antibody to be recovered.

C. Preparation of the Formulation

After preparation of the antibody of interest as described above, thepharmaceutical formulation comprising it is prepared. The antibody to beformulated has not been subjected to prior lyophilization and theformulation of interest herein is an aqueous formulation. Preferably theantibody in the formulabon is an antibody fragment, such as an F(ab′)₂,in which case problems that may not occur for the full length antibody(such as clipping of the antibody to Fab) may need to be addressed. Thetherapeutically effective amount of antibody present in the formulationis determined by taking into account the desired dose volumes andmode(s) of administration, for example. From about 0.1 mg/mL to about 50mg/mL, preferably from about 0.5 mg/mL to about 25 mg/mL and mostpreferably from about 2 mg/mL to about 10 mg/mL is an exemplary antibodyconcentration in the formulabon.

An aqueous formulation is prepared comprising the antibody in apH-buffered solution The buffer of this invention has a pH in the rangefrom about 4.5 to about 6.0, preferably from about 4.8 to about 5.5, andmost preferably has a pH of about 5.0. Examples of buffers that willcontrol the pH within this range include acetate (e.g. sodium acetate),succinate (such as sodium succinate), gluconate, histidine, citrate andother organic acid buffers. The buffer concentration can be from about ImM to about 50 mM, preferably from about 5 mM to about 30 mM, depending,for example, on the buffer and the desired isotonicity of theformulation. The preferred buffer is sodium acetate (about 10 mM), pH5.0.

An polyol, which acts as a tonicifier and may stabilize the antibody, isincluded in the formulation. In preferred embodiments, the formulationdoes not contain a tonicifying amount of a salt such as sodium chloride,as this may cause the antibody to precipitate and/or may result inoxidation at low pH. In preferred embodiments, the polyol is anonreducing sugar, such as sucrose or trehalose. The polyol is added tothe formulation in an amount which may vary with respect to the desiredisotonicity of the formulation. Preferably the aqueous formulation isisotonic, in which case suitable concentrations of the polyol in theformulation are in the range from about 1% to about 15% w/v, preferablyin the range from about 2% to about 10% whv, for example. However,hypertonic or hypotonic formulations may also be suitable. The amount ofpolyol added may also alter with respect to the molecular weight of thepolyol. For example, a lower amount of a monosaccharide (e.g. mannitol)may be added, compared to a disaccharide (such as trehalose).

A surfactant is also added to the antibody formulation. Exemplarysurfactants include nonionic surfactants such as polysorbates (e.g.polysorbates 20, 80 etc) or poloxamers (e.g. poloxamer 188). The amountof surfactant added is such that it reduces aggregation of theformulated antibody and/or minimizes the formation of particulates inthe formulation and/or reduces adsorption. For example, the surfactantmay be present in the formulation in an amount from about 0.001% toabout 0.5%, preferably from about 0.005% to about 0.2% and mostpreferably from about 0.01% to about 0.1%.

In one embodiment, the formulation contains the above-identified agents(i.e. antibody, buffer, polyol and surfactant) and is essentially freeof one or more preservatives, such as benzyl alcohol, phenol, m-cresol,chlorobutanol and benzethonium Cl. In another embodiment, a preservativemay be included in the formulation, particularly where the formulationis a multdose formulation. The concentration of preservative may be inthe range from about 0.1% to about 2%, most preferably from about 0.5%to about 1%. One or more other pharmaceutically acceptable carriers,excipients or stabilizers such as those described in Remington'sPharmaceutical Sciences 16th edition, Osol, A. Ed. (1980) may beincluded in the formulation provided that they do not adversely affectthe desired characteristics of the formulation. Acceptable carriers,excipients or stabilizers are nontoxic to recipients at the dosages andconcentrations employed and include; additional buffering agents;co-solvents; antoxidants including ascorbic acid and methionine;chelating agents such as EDTA; metal complexes (e.g. Zn-proteincomplexes); biodegradable polymers such as polyesters; and/orsalt-forming counterions such as sodium.

The formulation herein may also contain more than one protein asnecessary for the particular indication being treated, preferably thosewith complementary activities that do not adversely affect the otherprotein. For example, where the antibody is anti-CD18, it may bedesirable to provide a further anti-adhesion antibody, such as ananti-ICAM-1 or anti-CD11a antibody along with the anti-CD18 antibody ina single formulation. Alternatively, the anti-CD18 antibody may becombined with another anbinflammatory agent or a thrombolytic agent.Such proteins are suitably present in combination in amounts that areeffective for the purpose intended.

The formulations to be used for in vivo administration must be sterile.This is readily accomplished by filtrabon through sterile filtrationmembranes, prior to, or following, preparation of the formulation.

D. Administration of the Formulation

The formulation is administered to a mammal in need of treatment withthe antibody, preferably a human, in accord with known methods, such asintravenous administration as a bolus or by continuous infusion over aperiod of time, by intramuscular, intraperitoneal, intracerobrospinal,subcutaneous, intra-articular, intrasynovial, intrathecal, oral,topical, or inhalation routes. In preferred embodiments, the formulationis administered to the mammal by intravenous administration. For suchpurposes, the formulation may be injected using a syringe or via an IVline, for example.

The appropriate dosage (“therapeutcally effective amount”) of theantibody will depend, for example, on the condition to be treated, theseverity and course of the condition, whether the antibody isadministered for preventive or therapeutic purposes, previous therapy,the patient's clinical history and response to the antibody, the type ofantibody used, and the discretion of the attending physician. Theantibody is suitably administered to the patent at one time or over aseries of treatments and may be administered to the patent at any timefrom diagnosis onwards. The antibody may be administered as the soletreatment or in conjunction with other drugs or therapies useful intreating the condition in question.

As a general proposition, the therapeutically effective amount of theantibody administered will be in the range of about 0.1 to about 50mg/kg of patent body weight whether by one or more administrations, withthe typical range of antibody used being about 0.3 to about 20 mg/kg,more preferably about 0.3 to about 15 mg/kg, administered daily, forexample. However, other dosage regimens may be useful. The progress ofthis therapy is easily monitored by conventional techniques.

In the case of an anti-CD18 antibody, a therapeutically effective amountof the antibody may be administered to treat inflammatory disorders suchas hemorrhagic shock, thermal injury (such as that resulting fromburns), stroke (including ischemic and hemorrhagic stroke), andmyocardial infarction. Where the antibody is an antlL8 antibody, thedisorder may be an inflammatory disorder such as adult respiratorydistress syndrome (ARDS), hypovolemic shock, ulcerative colits, andrheumatoid arthritis.

E. Articles of Manufacture

In another embodiment of the invention, an article of manufacture isprovided comprising a container which holds the aqueous pharmaceuticalformulation of the present invention and optionally providesinstructions for its use. Suitable containers include, for example,bottles, vials and syringes. The container may be formed from a varietyof materials such as glass or plastic. An exemplary container is a 3-20cc single use glass vial. Alternatively, for a multidose formulation,the container may be 3-100 cc glass vial. The container holds theformulation and the label on, or associated with, the container mayindicate directions for use. The article of manufacture may furtherinclude other materials desirable from a commercial and user standpoint,including other buffers, diluents, filters, needles, syringes, andpackage inserts with instructions for use.

The invention will be more fully understood by reference to thefollowing examples. They should not, however, be construed as limitingthe scope of the invention. All literature and patent citations areincorporated herein by reference.

EXAMPLE 1

This example describes an aqueous formulation comprising the antibody,recombinant humanized anti-CD18 antibody (rhuMAb CD18). RhuMAb CD18having the amino acid sequence shown in FIG. 1A (heavy chain; SEQ IDNO:1) and FIG. 1B (light chain; SEQ ID NO:2) was created by humanizationof the murine monoclonal antibody muMAb H52 (Hildreth et al. J.Immunology 134:3272-3280 (1985)).

The rhuMAb CD18 was produced recombinantly as described below. PlasmidpS 1130 was constructed to direct production of a rhuMAb CD18 precursormolecule with a leucine zipper domain in E. coli. The precursor iscleaved during the purification process by the protease pepsin to yieldrhuMAb CD18. rhuMAb CD18 is an F(ab′)₂ molecule composed of twodifferent peptides (light and heavy chains) linked by disulfide bonds.Fusion of a yeast GCN4 leucine zipper dimerizabon domain to theC-terminus of an Fab′ substitutes for the Fc region and allows forefficient F(ab′)₂ production in E. coli. The GCN4 leucine zipper domainsinteract to form stable dimeric structures (parallel coiled coils) thathold the hinge region cysteine residues of two heavy chains together sothat the two native interchain disulfide bonds can form. This results information of F(ab′)₂ complexes that are covalently linked by disulfidebonds. The leucine zipper domains are later removed from the rhuMAb CD18precursor during the purification process using the protease pepsin,which cleaves uniformly between the two leucine residues of the hinge.This results in the formation of the rhuMAb CD18 F(ab′)₂ molecule.

Plasmid pS1130 (FIG. 20) is based on the well characterized plasmidpBR322 with a 2143 bp expression cassette (FIGS. 21A and 21B) insertedinto the EcoRI restriction site. Plasmid pS1130 is resistant to bothtetracycline and β-lactam antibiotics. The expression cassette containsa single copy of each gene linked in tandem. Transcription of each geneinto a single dicistronic mRNA is directed by the E. coli phoA promoter(Chang et al. Gene 44:121-125 (1986)) and ends at the phage lamda toterminator (Scholtissek and Grosse Nucleic Acids Research 15:3185(1987)). Translation initiation signals for each chain are provided byE. coli STII (heat stable enterotoxin) (Picken et al. Infection andImmunity 42:269-275 (1983)) Shine-Dalgarno sequences. Translation ofeach chain begins with a 23 residue STII signal peptide that directstranslocaton of the pepbdes across the cytoplasmic membrane into theperiplasmic space. The STII signal peptide is then removed by the E.coli leader peptidase. The light and heavy chains fold into their nativeconformations after secretion into the periplasm and associate into therhuMAb CD18 precursor, a covalently linked F(ab′)₂. The leucine zipperdomain is cleaved from the precursor during the purification process(see below) to yield rhuMAb CD18. The cell line used in the productionof rhuMAb CDI8 is 49A5, derived from E. coli cell line W3110 (ATCC27,325) as shown in FIG. 22. The fermentation procedure takes place asshown in FIG. 23. Production of rhuMAb CD18 precursor occurs when themedium becomes depleted in phosphate, typically 30-60 hours afterinoculation.

Purification of rhuMAb CD18 precursor from the E. coli cell paste was asfollows. Frozen cell pellets containing antCD18 precursor antibody, weredissolved in about 3 volumes of extraction buffer (120 mM MES, 5mM EDTAbuffer, pH 6) heated to 30-40° C. This resulted in a suspension with apH between about 5.4 and 6.5. This suspension was passed twice through aGaulin homogenizer at 5500 to 6500 psi and kept below 20° C. with a heatexchanger. 5% polyethyleineimine (PEI) (wh), pH 6 was added to thehomogenate to a final concentration of 0.2% PEI. The mixture wasincubated for about one hour at 2-8° C. About one volume of extractionbuffer (120 mM MES, 5 mM EDTA, pH 6) was added before the solids wereremoved by centrifugation at 15,280 g. The clear supernatant wasconditioned to a conductivity of less than 3mohms by the addition ofcold water. The conditioned supernatant was loaded onto a cationexchange column (ABX column; Mallinckrodt Baker, Inc., N.J., USA)equilibrated in 50 mM MES, pH 6.0. sodium citrate, pH 6.0. The cationexchange anti-CD18 precursor antibody pool was diluted with 50 mM MES,36 mM sodium citrate, pH 4.0 to a concentration of approximately 2 g/L.The pool was then adjusted to pH 4 by addition of 2 M citric acid andflowed through a column containing immobilized pepsin (pepsin-CPG)previously equilibrated with 50 mM MES, 36 mM sodium citrate pH 4.0.Pepsin (Sigma, Mo., USA) was chemically coupled to controlled pore glass(CPG) by Bioprocess Ltd., NJ, USA; the CPG was activated with NalO4followed by reduction of schiff base formation between CPG and pepsinusing NaBH3CN). This procedure removed the zippers from the hinge regionwhile leaving intact F(ab′)₂. The effluent from the pepsin-CPG columnwas filtered directly in line through an anion exchange Sartobind Qfilter (Sartorius, Goettingen, West Germany). The generated anti-CD18F(ab′)₂ antibody flows through the filter while pepsin and othernegatively charge impurities bind strongly to the filter. The pool wasdiluted to give a conductivity of approx. 7 mohms by the addition ofwater and was then applied to a cation exchange column (SP Sepharose HP)equilibrated was 25 mM MES, 60 mM acetic acid, pH 4.0. The SP Sepharosecolumn was washed with 25 mN MES, 75 MM sodium acetate pH 5.6 and elutedin a linear gradient of 75-110 mM sodium acetate in 25 mN MES pH 5.6.The pooled fraction from the SP sepharose column was diluted with theaddition of 3.0M ammonium sulphate, 25 mM MES pH 6.0 at a ratio of 0.26liters per liter of pool and was then passed through a hydrophobicinteraction chromatography (HIC) column (phenyl sepharose FF-lowsubstitution) previously equilibrated in 0.625 M ammonium sulphate, 25nM MES pH 6.0. After loading, the column was washed with same bufferused in equilibration and the rhuMAb CD18 was eluted in 0.375M ammoniumsulphate, 25 mN MES pH 6.0.

This resulted in purified rhuMAb CD18 for formulating as describedbelow. Five aqueous formulations were evaluated for selection of aclinical formulation for use in, e.g., hemorrhagic shock. Theformulations were as shown in Table 1 below.

TABLE 1 Matrix of formulations prepared for this study. TWEEN 20 ™ NaClMannitol Trehalose Formulation Buffer pH (0.01% v/v) (140 mM) (4% w/v)(8% w/v) F1 10 mM 5.0 + + Acetate F2 10 mM 5.0 + + Acetate F3 10 mM6.0 + + Histidine F4 10 mM 6.0 + + Histidine F5 10 mM 6.0 + + Histidine

Two pH's were compared, pH 5 (sodium acetate) and pH 6 (histidine). Ateach pH, sodium chloride and trehalose were compared as tonicifiers. Ahistidine formulation with mannitol at pH 6 was also evaluated. Thepresence of a surfactant (e.g. 0.01% TWEEN 20™) was found to be requiredfor stabilization against shaker-induced aggregation and for preventingadsorption to containers at protein concentrations below 1 mg/mL. Thestability assays indicated that the trehalose formulations weregenerally superior to the others, with pH 5 showing slightly greaterchemical stability than the pH 6 formulation due to reduced clipping.Kinetic data after 2 weeks and 5 weeks storage at 5, 30, and 40° C. wereused for Arrhenius analysis and shelf-life prediction. Using cationexchange HPLC, the preferred formulation for rhuMAb CD18 was 10 mMsodium acetate, 8% trehalose whv, 0.01% TWEEN 20™, pH 5.0, with apredicted shelf life of 25-75 months (95% confidence intervals) at 5° C.

In designing antibody formulations, it may be useful to analyze thestructural properties of the antibody to be formulated, but this is notnecessary. RhuMAb CD18 consists of beta sheets of light (left side ofthe molecule in FIG. 16) and heavy chains (right side of the molecule inFIG. 16) which are structurally stabilized each by two intramoleculardisulfides and held together by two intermolecular disulfides (depictedas barrels at the bottom of FIG. 16). The CDRs (complimentaritydetermining regions) in the variable segments are oriented on the top ofthe molecule. Located within and close to the CDRs are a number ofmethionines, only one of which (Met 65) is fully exposed. Though Met 65is buried in anti-CD18, it is near a histidine residue which, withoutbeing limited to any one theory, might promote metal induced oxidationof proximal methionine (Li et al. Biochem. 34(17):5762-5772 (1995)).Susceptibility to oxidation in the CDRs was assessed herein. It wasfound to be desirable to use a sugar as the tonicifler, rather than asalt, so as to minimize oxidation at low pH.

In assessing the potential deamidation or isomerization sites in thismolecule, i.e. Asx-Gly or Asx-Ser (Asx indicates Asp or Asn) that are inhydrophilic and flexible regions (Clarke et al. in Stability of ProteinPharmaceuticals. Part A. Chemical and Physical Pathways of ProteinDegradation, T. J. Ahern and M. C. Manning, Editors. 1992, Plenum Press:New York. p.2-29; and Kossiakoff, Science, 240:191-94 (1988)), six werefound to be exposed and in fairly flexible regions (FIGS. 2A and 2B).Without being limited to any one theory, heavy chain motifs MN⁸⁴S,KN⁵⁵G, and light chain motifs GN¹⁵⁸S, QD¹⁶⁷S, KD¹⁷⁰S, are predicted tobe most reactive; reactivity at Asn 84 is most likely to affect thebinding activity of the antibody since it is near the CDR's. Asn 103 wasfound to be the primary route of degradation (via deamidation).

MATERIALS AND METHODS

The materials used in the following methods were as follows: glacialacetic acid 99.9% (MW 60.05); concentrated NaOH 18.94N (50% w/w; MW40.0); concentrated HCI 37.8% (12.44N; MW 36.46); hisbidine (MW 155.16);NaCl (MW 58.44g); pharmaceutical grade trehalose dihydrate (MW 342.31);D-mannitol (MW 182.17); low peroxide TWEEN 20™; rhuMAb anti-CD18 (˜1.3mg/mL in MOPS, Na acetate, pH 6.9).

Buffer preparation and formulation set-up: Two liters of the followingstock buffers were prepared for dialysis and formulation:

0.2 M Sodium Acetate, pH 5: 22.7 mL acetic acid, 17 mL 50% NaOH, made upto 2 L with Milli-Q water. Final pH 4.98. The solution was sterilefiltered into 2 L Nalgene bottles and stored at 5° C.

0.2 M Histidine, pH 6: 62.06 g of Histidine, 20 mL concentrated HCI,made up to 2 L in a volumetric flask. Final pH 5.92. The solution wassterile filtered into 2 L Nalgene bottles and stored at 5° C.

2 M NaCl: 116.88 g NaCl, made up to 1 L with Milli-Q water. The solutionwas sterile filtered into 1 L Nalgene bottles and stored at 5° C.

18% Mannitol: 180 g mannitol, made up to 1 L with MilliQ water. Thesolution was sterile filtered into 1 L Nalgene bottles and stored at 5°C.

20% Trehalose: 400 g trehalose, made up to 2 L with Milli-Q water. FinalpH was 6.4. The solution was sterile filtered into 2 L Nalgene bottlesand stored at 5° C.

10% (v/v) TWEEN 20™: 10 mL of concentrated TWEEN 20™ was carefullyremoved and added to a 100 mL volumetric flask, diluted with Milli-Qwater, and stirred until dissolved. Stored at 2-8° C. in the dark.

Formulation: Table 2 below shows the preparation of the buffers againstwhich the starting protein bulk was dialyzed for this study.Approximately 40 mL of the bulk rhuMAb CD18 (˜1 .3mg/mL proteinconcentration) was dialyzed (2 L for 4 hr at 5° C. and ˜2 L overnight)to solutions prepared as shown in Table 2. The dialyzate was filteredwith 0.2 μM Nalgene cellulose acetate filter units and stored underaseptic conditions for use as blank for UV and HPLC analysis.

TABLE 2 Summary of formulation preparation 0.2 M 18% 20% Approx. Made upbuffer Mannitol Trehalose 1M NaCl Water to Formulation (mL) (mL) (mL)(mL) (mL) pH final pH (mL) F1 Acet/5 200 — — 560 3000 5.07 5.07 4000 F2Acet/5 200 1600 2000 5.17* 5.07 4000 F3 His/6 200 — — 560 3900 6.03 6.034000 F4 His/6 200 889 — 2800 5.85* 6.01 4000 F5 His/6 200 — 1600 20005.97 5.97 4000 *Formulation F2 was adjusted with acetic acid buffer madeby diluting 286 μL of glacial acetic acid and 200 mL of the 20%trehalose and mixed with Milli-Q water to a final 500 mL. This is 10 mMacetic acid with 8% trehalose. Approximately 250 mL was required toadjust the pH as required. Formulation F4 was adjusted with 0.5 mL of50% NaOH.

Some of the remaining dialysis buffer was used to prepare formulationvehicles by adding TWEEN 20™, as shown in Table 3.

TABLE 3 Summary of preparation of formulation vehicles Dialysis 10%Final Buffer TWEEN 20 ™ Vol. Vehicle (mL) (μL) (mL) F1 41.4 41 41.4 F241.5 42 41.5 F3 42.4 42 42.4 F4 42.2 42 42.2 F5 41.4 41 41.4

Table 4 below shows the final appearance, pH, and protein concentrationof the dialyzed protein solutions.

TABLE 4 Summary of analysis of the dialyzed protein solutions OD280diluted Conc. = pH of protein color/ Temp Formulation 1:1 OD/1.32^(c)solution Vehicle pH appearance ° C. F1 0.8239 1.248 5.09 5.09  CAC**24.7 F2 1.1192 1.696 5.09 5.09 CAC 24.7 F3 0.84605 1.282 6.06 6.06 CAC24.7 F4 0.89763 1.36 6.10 6.10 CAC 24.7 F5 1.116 1.69 5.91 5.91 CAC 24.7*Extinction coefficient was later changed to 1.45 mL/mg/cm. **CAC =clear and colorless.

These protein solutions were then diluted, using reserved dialysisbuffer, to a final ˜1 mg/mL protein concentration, and TWEEN 20™ wasadded to final 0.01% (v/v), as shown in Table 5.

TABLE 5 Summary of final formulation concentration adjustment andconcentration determination Dialysis 10% Dialy. Starting Final *FinalForm. buffer TWEEN 20 ™ Protein Conc. Vol. *Final Conc. *OD no. (mL)(μL) (mL) (mg/mL) (mL) OD280 (mg/mL) 340-360 F1 8.16 41 33.2 1.248 41.41.3297 1.008 0.011 F2 17.0 42 24.5 1.696 41.6 1.3332 1.010 0.017 F3 9.2642 33.1 1.282 42.4 1.3138 0.995 0.009 F4 11.2 42 31 1.36 42.2 1.30650.990 0.010 F5 16.9 41 24.5 1.69 41.4 1.3118 0.994 0.016 *Measured afterfiltration and filling.

The formulations were sterile filtered using 150 mL Nalgene filter unitswith cellulose acetate membranes in a sterile hood. The sterileformulated rhuMAb CD18 solutions were filled at 0.6 mL per 3 cc vial,labeled and stored at designated temperatures. Vehicle solutions werefiltered and filled identically. Tables 6A (antibody formulations) and6B (vehicle controls) below show the stability program for theseformulations. Data presented here are up to 5 weeks storage.

TABLE 6A CD18 antibody formulations 40° C. 30° C. 5° C. −20° C. −70° C.time samples samples samples samples samples t0 2 2 2 2 wk 2 2 2 5 wk 22 2 2 2 8 wk 2 2 2 12 wk  2 2 2 2 2 6 mo 2 2 2 2 9 mo-1 yr 2 2 2 2 8 + 2ext = 10 12 14 8 10 + 4 ext = 14

TABLE 6B Vehicles 40° C. 30° C. 5° C. −20° C. −70° C. time vehiclesvehicles vehicles vehicles vehicles t0 1 1 1 2 wk 1 1 1 5 wk 1 1 1 1 2 8wk 1 1 1 12 wk 1 1 1 1 2 6 mo 1 1 1 2 1 yr 1 1 1 2 4 6 6 + 2 = 8 4 + 2 =8 8 + 2 ext

At the 2 week and 5 week timepoints, 2 vials from each formulation andstorage temperature were frozen at −70° c. At the 5 week timepoint thefrozen samples were thawed and batch analyzed together with controlsamples frozsen at −70° C. immediately after filling (t=0 weeks).

UV Spectroscopy: Samples were measured without dilution in a HeIlma 2 mmwide, 1 cm path-length cell with raised bottom and black sides.Approximately 300 μL of sample was used for the measurements. Theinstrument was blanked with Milli-Q water. Samples were scanned from 200to 400 nm with a 2 nm bandwidth and 1 second integration using aHP-8452A spectrophotometer.

Protein concentration was determined from the absorbance at 278 nmcorrecting for the absorbance at 320 nm using an extinction coefficientof 1.45 mL/mg/cm. The average value of absorbances in the region of A₃₄₀to A₃₆₀ was followed as an indicator of scattering material.

pH: An Orion 720A pH meter was used with a MicroElectrodes, Inc. MI-410micro pH electrode. The electrode was calibrated with pH 4 and 7standard buffers, re-checked every 10-15 samples, and recalibrated asrequired. The instrument was calibrated and samples were measured atroom temperature (˜23° C.).

RP-HPLC: RP-HPLC was carried out using a 7.5×75 mm TSK Phenyl-5PW columnwith 0.1% TFA as the A buffer, and 0.08% TFA in acetonitrile as the Bbuffer. An inline 0.5,M filter was used before the column wasequilibrated at 10% B buffer and run at 55° C. Injections of 20 μL weremade and eluted according to Table 7 below:

TABLE 7 Time Flow (Minutes) % B (mL/minute) 0 10 0.8 30 25 0.8 35 70 0.835.01 70 2 36 70 2 37 10 2 41 10 2 Data collected at 214 nm at 1 pointper second were used for analysis.

SEC Assay: The mobike phase used was 200 mM NaCl, 50 mM sodium phosphateat pH 6.0. The runs were 40 minutes at a flowrate of 0.5 mL/minute with40,μL injectons done at ambient temperature. A TSK G3000SWXL 30 cm×7.8mm column with inline filter and a TSK guard column before the maincolumn was used. Detection was at 214 nm.

Ion-Exchange HPLCAssay(IEX): IEX was run using 50 μL injections. Themobile phases were 33 mM each of MES/HEPESIPIPES, adjusted to pH 6.0 forA and pH 8.0 for B; C=Milli-Q water. The gradient shown in Table 8 belowwas used:

TABLE 8 Time Flow (min) % B % C (mL/min) 0 0 50 1 3 0 50 1 15 20 50 1 5050 50 1 50.1 100 0 2 51 100 0 2 51.1 0 50 2 60 0 50 2

The method used a 50×4.6 mm BakerBond carboxy-sulphon (CSx) cationexchange column with an inline 0.5 μM filter before the column, run at40° C. Analysis was done with data obtained at 280 nm, due to the highbuffer background.

Hydrophobic Interaction Chromatography (HIC): HIC was done on a 4.6×50mm Baker Bond Butyl NPR column with inline 0.5 μM filter before thecolumn. The running buffers were 2M ammonium sulfate in 20 mM Tris-HCI,pH 7 as the A buffer, and 20 mM Tris, pH 7 as the B buffer. The columnwas equilibrated at 50° C. with 10% buffer B at 1 mUminute and 10 μLinjections were made. The gradient shown in Table 9 below was used forelution:

TABLE 9 Time % B 0 10 1 10 35 100 37 100 37.1 10 42 10 Data werecollected at 214 nm at 1 point per second.

SDS-PAGE: Pre-made 10 and 14% glycine SDS-PAGE gels (Novex, San Diego,Calif.) were used for analysis of the reduced and non-reduced samples,respectively. 10 μL of the 1 mg/mL sample diluted with 10 μL of2×Tris-Glycine sample buffer (Novex) was heated 2 minutes at 95° C., aswere high MW range and low MW range (Bio-Rad) markers diluted 1:20 insame sample buffer. Kaleidoscope MW marker was heated at 95° C., aswell, with no dilution. When the samples cooled, 10 μL was loaded on thegels. The load of the MW marker solutions was 5 μL. The gel apparatus(Novex) was filled with 1×gel loading buffer (Media Services) and thegels were run at constant voltage of 125 mV and variable current for 2hours. The gels were stained with the Novex Coomassie blue stain,overnight. The next day, the gels were washed with water for 2 hours andthen were soaked in Gel Drying Solution (1×) (Novex) for ½ hour. Thegels were then air-dried with the Novex cellophane system.

Gel Isoelectric Focusing Electrophoresis: IEF was done using Pharmacia3.5 to 9.5 PAG plate gels. Pharmacia phosphoric acid and sodiumhydroxide running buffers were used. Samples were prepared by mixing 10μL of sample with 30 μL of 15% glycerol. Pharmacia broad range and highrange IEF standards, as well as Serva Protein Test Mix 9 were run as pimarkers. Pharmacia standards were prepared by mixing the standard(reconstituted with 0.5 mL of Milli-Q water) 1:1 with 15% glycerol. TheServa protein mix was reconstituted according to instructions anddiluted 10-fold with 15% glycerol. On one gel, anti-HER2 MAb bulk(pl=8.8-9.0 calculated) was also run as a control. The HER2 sample (5mg/mL) was diluted 40× with 15% glycerol. The gels were loaded with 20μL of each sample adsorbed onto paper patches placed one third of thegel width from the positive electrode (the acid side). Gels were run at10° C. with constant voltage set to 400 V for 30 minutes, after whichthe sample loading papers were removed and the gels were run for 1.5more hours at 1500 V. Gels were fixed in TCA with sulfosalicylic acidfor 30 minutes, and washed with water for 10 minutes (for the secondgel) or IEF destain (for the third gel), and stained without washing outthe TCA, as instructed in the Novex instructions (for the first gel).The first two gels were stained with Novex colliodal Coomassie accordingto the Novex instructions. The last gel was stained for 8 minutes withstandard IEF Coomassie stain which was preheated to ˜60° C., and thendestained with IEF destain which had also been preheated to ˜60° C.overnight. The gels were air-dried with the method described above forthe SDS-PAGE gels.

Freeze/ThawStability: To demonstrate that rhuMAb CD18 would not degradeby freeze/thaw cycling in the formulations being tested, four vials ofeach formulation were subjected to three cycles of freezing and thawing.Two of the vials of each formulation were cycled between −70° C. and2-8° C. and two were cycled between −20° C. and 2-8° C. Two vials ofeach formulation were held at 2-8 ° C. as controls. During each cyclethe vials were allowed to remain in the freezer for at least 2 hours,until there was no visible liquid remaining in the vial. They were thentransferred to 2-8° C. for at least 2 hours, until no solid remained.One vial of the acetate/trehalose, pH 5 formulation (F2) did not freezeat −20° C. on the first cycle, but froze immediately when placed on theshelf in a −70° C. freezer.

Shaker Studies: One vial of each formulation, and a vial of identicallyconfigured rhuMAb CD18 bulk, was placed horizontally into a rack on aGlas-Col 99A S60012 shaker. The shaker arm was adjusted to a radius of˜30 cm and the speed was set to 70 rpm. The samples were shaken for 24hours at room temperature in the axial direction. A second vial of eachformulation, and the bulk, was maintained at room temperature near theshaker, as a control. The samples were then analyzed by IEX, MAC-1capture assay, and UV spectroscopy.

MAC-1 Capture (Receptor ELISA) and Total F(ab′)₂ ELISA: rhuMAb CD18 isdirected to the CD18 chain of MAC-1. The antigen binding property ofrhuMAb CD18 can hence be evaluated by “MAC-1 capture assay”. The assayinvolves coating of a 96 well mictrotitre plate first with a murineanti-CD18 antibody that binds to a site of MAC-1 different from rhuMAbCD18 (MHM23 MAb; Hildreth et al, Eur. J. Immunol. 13:202-208 (1983)) tocapture a recombinant preparation of soluble MAC-1, followed by a washwith phosphate buffered saline (PBS), addition of the unknown sample,wash with PBS, addition of goat HRP-labeled anti-human F(ab′)₂ antibodyand colorimetric detection of OPD substrate. The total amount ofantibody is measured by first coating an ELISA plate with a polyclonalanti-F(ab′)₂ antibody, followed by addition of the sample, and thenHRP-anti F(ab′)₂ and calorimetric detection of the HRP substrate OPD.Assay diluents in both cases were 0.5% bovine serum albumin (BSA), 0.05%polysorbate 20, 1 mM CaCl₂, 1 mM MgCl₂ Specific activity was measured asthe ratio of the MAC-1 binding to total F(ab′)₂ ELISA value.

The samples were serially pre-diluted with assay diluent obtained tofinal dilutions of 20,000, 40,000, and 80,000 times in microtiter platesand Micronics tubes using multi-channel pipettors. The dilution schemeused was as shown in Table 10 below. Samples of diluted rhuMAb CD18 bulkwere included on each assay plate as controls. These bulk controls werediluted one extra 2×dilution to final 40,000, 80,000, and 160,000 times.The same dilutions were used for both assays. Samples were diluted thesame day as they were thawed for the 5 week analysis and then frozen inthe Micronics tubes prior to submission for assay the following day. Thefreezelthaw stability of rhuMAb CD18 diluted in assay diluent in theseassays was verified.

TABLE 10 Dilution Sample Diluent Step (times) (μL) (μL) 1, in 96 wellplate* 10 10 90 2, in 96 well plate* 10 10 90 3, in 96 well plate* 10 1090 4, in Micronics tubes 20 50 950 5, in Micronics tubes 2 500 500 6, inMicronics tubes 2 500 500 *Later studies were conducted by making alldilutions in Micronics tubes and vortexing them to mix; this improvedreproducibility.

Kinetic Parameters, Arrhenius Calculations, and Statistics: The loss inthe % main peak versus time was fitted to first order kinetics. Theobserved rate constants (K) at various temperatures were then fitted tothe Arrhenius equation as shown below:

In K=−ΔE/RT+C

where E is the activation energy (in cal/mol), R is the Universal gasconstant (1.987 cal/mol/K), T is the absolute temperature (in Kelvins)and C is a constant. From the slope of a plot of In K VS. 1/T, ΔE wascalculated. The standard error (SE) of In K was calculated using theformula [(1/K)²+(SE)²]^(0.5). The reason for a large SE value for In Kat lower temperatures is the small value of the K which is in thedenominator of the formula. A value of K extrapolated from the Arrheniusfit (±95% confidence interval) was used to predict the shelf life at 5°C. according to:

t₉₀(wk)=In 0.9/K

where K was expressed in weeks⁻¹. Confidence intervals were determinedusing the program SIGMAPLOT™.

RESULTS AND DISCUSSION

Freeze/Thaw stability: Table 11 below shows a summary of the data fromanalysis of the samples in the freeze/thaw study. No significantdifferences were seen between the different temperature groups. Theobservation that one vial of F2 did not freeze at −20° C. on the firstcycle raised a concern that freezing of bulk in a jacketed stainlesssteel storage tank might be problematic. The coldest parts of thesolution in these tanks reach only about −20° C., and therefore mightnot freeze completely. This was tested using formulation vehicle. Thetank was observed to freeze solid within 6 hours of cooling, so noproblem for bulk storage is predicted.

TABLE 11 Effect of three cycles of freezing and thawing to 5° C. on theStability of rhuMAb CD18 MAC-1 Capture RP-HPLC RP-HPLC SEC SEC UV Conc.UV Average Titer Specific Activity Formulation Total Area % Main TotalArea % Main (mg/mL) 340-360 nm (μg/mL) (MAC-1/UV) F1 5° C. 10276 ± 2588.0 ± 0.1 6401 ± 151 83.8 ± 0.4 0.949 ± 0.003 0.011 ± 0.001 1000 ± 321.05 ± 0.03 −20° C. 10341 ± 106 88.2 ± 0.1 6556 ± 73 83.2 ± 0.1 0.952 ±0.002 0.012 ± 0.001 948 ± 28 1.00 ± 0.03 −70° C. 10328 ± 13 87.5 ± 0.016353 ± 63 83.0 ± 0.9 0.948 ± 0.005 0.013 ± 0.004 972 ± 15 1.03 ± 0.02 F25° C. 10537 ± 4 88.5 ± 0.2 6508 ± 18 81.7 ± 0.3 0.941 ± 0.006 0.017 ±0.005 1069 ± 57 1.14 ± 0.06 −20° C. 10644 ± 107 87.3 ± 0.5 6290 ± 5483.1 ± ± 0.2 0.941 ± 0.002 0.012 ± 0.001 1132 ± 27 1.20 ± 0.03 −70° C.10503 ± 74 88.5 ± 0.2 6435 ± 120 82.5 ± 0.8 0.938 ± 0.000 0.009 ± 0.0021064 ± 41 1.13 ± 0.04 F3 5° C. 10147 ± 50 87.9 ± 0.2 6311 ± 65 84.8 ±0.3 0.926 ± 0.002 0.017 ± 0.001 1017 ± 77 1.10 ± 0.08 −20° C. 10050 ± 4388.4 ± 0.00 6404 ± 39 85.6 ± 0.1 0.922 ± 0.007 0.012 ± 0.001 997 ± 281.08 ± 0.03 −70° C. 9953 ± 85 88.0 ± 0.2 6356 ± 52 83.9 ± 0.2 0.926 ±0.002 0.017 ± 0.005 1021 ± 26 1.0 ± 0.03 F4 5° C. 10397 ± 26 88.2 ± 0.16304 ± 148 84.5 ± 1.1 0.921 ± 0.000 0.010 ± 0.003 905 ± 18 0.98 ± 0.02−20° C. 10126 ± 180 88.6 ± 0.03 6467 ± 13 83.5 ± 0.2 0.922 ± 0.004 0.014± 0.001 1004 ± 20 1.09 ± 0.03 −70° C. 10322 ± 51 88.l ± 0.1 6327 ± 384.7 ± 1.1 0.924 ± 0.004 0.009 ± 0.007 982 ± 21 1.06 ± 0.03 F5 5° C.10438 ± 81 88.0 ± 0.1 6418 ± 64 85.9 ± 0.3 0.930 ± 0.001 0.016 ± 0.0041058 ± 39 1.14 ± 0.04 −20° C. 10443 ± 10 88.3 ± 0.1 6310 ± 11 86.5 ± 0.40.923 ± 0.004 0.016 ± 0.003 1010 ± 49 1.09 ± 0.05 −70° C. 10350 ± 13588.3 ± 0.00 6340 ± 58 85.5 ± 0.1 0.923 ± 0.003 0.017 ± 0.006 1003 ± 221.09 ± 0.02 Mean ± SE of two vials are shown. No significant loss inmonomer content or receptor binding was noticed.

UV Spectroscopy: Spectroscopic analysis of the samples was done tomeasure protein concentration as well as to measure light scattering asindicated by an increase in average absorbances in the range of 340 to360 nm, or by a decrease in the ratio of the absorption maxima at 278 nmand the minima at 252 nm. FIGS. 3A and 3B show a summary of the UV data.The 40° C. samples of formulation F3 were very cloudy, containing whiteflocculent particles. These samples were microfuged for 5 minutes at14000 RPM and re-measured after which the scatter was still relativelyhigh. All other samples appeared clear and colorless (A₃₄₀₋₃₆₀<0.02,A₂₇₈/A₂₅₂>2.4). The change in A278/A250 was a more sensitive indicatorof scattering than the average absorbances from 340 to 360 nm, since thelatter showed no storage temperature related trend (FIG. 3A), but theformer showed a definite increase for the 40° C. samples (FIG. 3B). ThepH 5 formulations showed a smaller change in A278/A252 ratio at 40° C.than the pH 6 formulations in every case. The protein concentrations forthe pH 5 formulations were only 2-3% greater than the pH 6 formulations(FIG. 4).

pH: All formulation vehicles except F4 showed a slight increase (˜0.1units at 40° C.) in pH, compared with −70° C. controls (Table 12 below).Both pH 5 formulations showed a greater pH increase in the activesamples than in the vehicles. None of the pH 6 formulations showed thisdifference between active and vehicle samples. In fact, the pH increaseseen in the F3 and F5 vehicles was not seen in the active samples. ThepH of F4 decreased slightly at higher storage temperature. The pHincrease in the pH 5 samples could be explained by a loss in acetic acidconcentration due to diffusion through the topper, and is not expectedto be significant at 5° C.

TABLE 12 Formulation pH after 5 weeks storage. pH of Active Sample pH ofVehicle (both vials shown) F1 at −70° C. 4.892 5.009/5.026 F1 at −20° C.4.894 5.028/5.035 F1 at 5° C. 4.947 5.077/5.082 F1 at 30° C. 5.0405.154/5.164 F1 at 40° C. 5.045 5.171/5.171 F2 at −70° C. 5.0375.179/5.089 F2 at −20° C. 5.041 5.096/5.101 F2 at 5° C. 5.0985.151/5.153 F2 at 30° C. 5.134 5.192/5.213 F2 at 40° C. 5.1365.242/5.215 F3 at −70° C. 6.123 6.164/6.154 F3 at −20° C. 6.1626.155/6.138 F3 at 5° C. 6.160 6.130/6.086 F3 at 30° C. 6.204 6.138/6.090F3 at 40° C. 6.214 6.098/6.075 F4 at −70° C. 5.964 6.014/6.016 F4 at−20° C. 6.017 6.050/6.019 F4 at 5° C. 6.021 6.004/5.988 F4 at 30° C.5.928 5.914/5.897 F4 at 40° C. 5.880 5.849/5.854 F5 at −70° C. 5.6535.751/5.754 F5 at −20° C. 5.729 5.761/5.766 F5 at 5° C. 5.7275.768/5.777 F5 at 30° C. 5.797 5.843/5.833 F5 at 40° C. 5.8125.822/5.831

The pH 5 formulations showed a small increase in pH at higher storagetemperatures for the vehicles and active samples. Formulations F3 and F5showed increasing pH in the vehicles with higher storage temperature,but the active samples did not show this increase. Formulation showed aslight reduction in pH.

SEC: FIGS. 5A and 5B show the chromatograms for formulations F2 (FIG.5A) and F5 (FIG. 5B). The main peak of rhuMAb CD18 eluted at 18.6minutes, corresponding to an apparent MW of ˜70,000 D. There were twomajor impurity peaks that eluted after the main peak, and the one at20.9 minutes increased considerably with increasing time and storagetemperature. The increase in the peak at 20.9 minutes was much morepronounced in F5 (FIG. 5B) compared to F2 (FIG. 5A), without beinglimited to any one theory, most likely due to the higher pH of F5. FIGS.6A and 6B show graphs of the total peak area and the % main peak for allof the formulations after 0, 2 and 5 weeks of storage at 5, 30 and 40°C. The total peak areas for formulations F3 and F4 were significantlylower than the other three formulations.

Since the lower pH formulations showed the greatest stability, rate datafrom the % main peak of the SEC chromatogram were calculated and fittedto an Arrhenius plot. Data for F2 is shown in FIG. 7. This plotcontained only two useful points since the rate constant at 5° C. had alarge standard error. The activation energy obtained from these data(19±6 kcal/mol) was very similar to the one calculated from the IEX data(see FIG. 15) even without the 5° C. datum. The 95% confidence intervalsto the curve fit predict a shelf-life from 6 to 60 years at 5° C.

HIC: This assay was performed at a column temperature of 50° C. ratherthan 55° C. to improve protein recovery (from ˜30% to nearly 90%),unfortunately at the expense of loss in resolution. HIC analysis of thestability samples showed an increase in a poorly resolved peak on theleading shoulder of the main peak, as well as an increase in a 17.5 minpeak with increasing storage time and temperature for all formulations(FIG. 8). The shoulder was in a position that would be consistent withan oxidized form of the protein, though in preliminary assessment nopeaks corresponding to an oxidized species appeared by peptde mapping.F2 showed the smallest increase in this leading peak (FIG. 9). A trendtowards reduced recovery (total area) was also seen with increasingstorage temperatures, with all formulations showing the same total areaat 40° C. (FIG. 10). Formulations F2 and F5 showed the least change intotal area at 5 and 30° C. relative to the starting −70° C. sample. Thismethod was not stability indicating because the resolution between thedegradation peak at 17.5′ and the main peak is too low for accuratequantitation, and the recovery from the method is poor.

RP-HPLC: The only change observed by RP-HPLC was an increase in a peakeluting at about 25 minutes, with a corresponding reduction in the mainpeak area, as the storage temperature increased (FIGS. 11 and 12). Themagnitude of this change was similar to that of the lower MW speciesseen in SEC. Based on the relative position of this peak and its area,it may correspond to the low MW species. Formulation F2 showed the leastchange in the % main peak area with increasing temperature. Samplesreduced with DTT were also run on RP-HPLC to increase the chance that anoxidized form might be resolved from one of the separated smallersubunits of the antibody. No difference was seen between the storedsamples and the −70° C. control samples with this method.

The Arrhenius plot of the RP-HPLC kinetic data for formulation F2 gave asimilar activation energy (21±1 kcal/mole) to the SEC and IEX results(19-20 kcal/mole) (FIG. 13). The shelf-life indicated by the 95%confidence intervals to the curve fit is 4 to 150 years at 5° C.

IEX: By this assay, earlier eluting peaks with retention times of 18.4and 26.6 minutes increased with increasing storage temperature. As shownin FIGS. 14A and B which represent formulations F2 and F5, respectively,there was a more pronounced increase of these peaks in F5, compared toF2. Also the peak at 19.5 minutes became broader at higher temperatures.Based upon chromatographic changes seen upon exposure of samples to pH11 (see below), this method should readily detect changes such asdeamidation and/or disulfide scrambling, both of which can be induced atalkaline pH.

Table 13 below shows the first order rate constants for the 5formulations at 5, 30, and 40° C.

TABLE 13 First order rate constants (κ ± SE; n = 2) for all formulationsbased on % main of IEX Form- ulation 5° C. 30° C. 40° C. F1 0.00064 ±0.0021 0.0083 ± 0.0014 0.0299 ± 0.0023 F2  0.0065 ± 0.0023 0.0091 ±0.0025 0.0245 ± 0.0040 F3 −0.0004 ± 0.0008 0.0143 ± 0.0010 0.0432 ±0.0019 F4 −0.00066 ± 0.00073  0.0137 ± 0.00033  0.0413 ± 0.00022 F5−0.00010 ± 0.00082  0.0129 ± 0.00095 0.0439 ± 0.0017

Formulations F1 and F2 are clearly better than the other formulations,implying that the major degradation process is base catalyzed. AnArrhenius plot based on the % main peak area predicted an activationenergy of 19.8±9.9 kcal/mole for F2 and a t₉₀ of 50±25 months (95%confidence intervals) at 5° C. (FIG. 15). Receptor binding activity:Table 14 below shows the specific activity for each temperature andformulation after 5 weeks storage. The specific activity was calculatedby dmding the MAC-1 capture assay concentration by the total F(ab′)₂ELISA concentration. The standard error shown is for n=2 and accountsfor the total propagated error from the two different assays for 2 vialsat 3 dilutions each. There was a clear trend for all formulationstowards a lower specific activity at higher storage temperatures(˜10-15% loss at 40° C.); all formulations showed about the same extentof loss at 40° C. relative to ˜70° C. The p value from one way ANOVAanalysis of the 40° C. data for the different formulations is 0.98, sothe 40° C. means would not be considered significantly different fromeach other, within 95% confidence. An unpaired t-test of the 40° C. dataversus the 30° C. data shows that the difference is significant(p=0.044) and the lower temperatures are even more significantlydifferent by this method (p<0.02).

TABLE 14 Storage F1 F2 F3 F4 F5 Temp (° C.) mean SE mean SE mean SE meanSE mean SE −70 0.976 0.098 0.906 0.140 1.008 0.112 0.952 0.116 0.9180.433 −20 0.978 0.123 0.903 0.157 0.946 0.152 0.871 0.072 0.865 0.209 50.982 0.157 0.898 0.177 1.023 0.166 0.919 0.203 0.886 0.350 30 0.9230.067 0.878 0.189 0.949 0.076 0.868 0.109 0.885 0.340 40 0.866 0.1130.817 0.227 0.904 0.115 0.817 0.093 0.772 0.198

IEF: The effect of storage for 5 weeks at different temperatures wasassayed by isoelectric focusing electrophoresis (IEF) for formulationsF2 and F5. The major band appeared to have a pI of ˜8.8. Three maincomponents at pl's ˜8.75 (second most intense band), ˜8.6, and ˜8.4 werealso seen, which increase slightly with storage, particularly at pH 6.The 30 and 40° C. samples showed conversion to the more acidic bands.For the 40° C. samples, the bands at pl 8.8 and 8.75 had approximatelyequal intensity and there was no discernible difference between theformulations in this regard. There were at least two more acidic bands(pl's ˜8.6 and ˜8.4), which had at least 4-fold lower intensity than thetwo most basic bands. These bands did not seem to change in intensitywith storage.

SDS-PAGE: The effect of storage temperature on the stability of rhuMAbCD18 formulations F2 and F5 (5 weeks) was assayed by SDS-PAGE (underreduced and nonreduced conditions). The rhuMAb CD18 appeared at a MW of˜120 kD on the non-reduced gel. In the starting bulk there were severalminor bands at higher molecular weight than the main band which mayrepresent rhuMAb CD18 with various portions of the leucine-zippersegment sill attached. Several percent of this impurity is known to bepresent in this bulk preparation. There were several bands of lower MWthan the main band, but only one of these bands seemed to change in anyof the formulations, or with temperature. The band at around 45 kDincreased with temperature and seemed slightly more intense in pH 6 thanin pH 5 formulations. This observation was consistent with SEC data. Theband just above the ˜45 kD band on the non-reduced gels corresponded inapparent molecular weight with the band seen on the reduced gels and mayrepresent a non-reducing contaminant protein. All species converted totwo bands, corresponding to light and heavy chain, upon reduction withdithiothreitol, suggesting the absence of any proteolytic cleavage.MALDI-TOF MS (Yates, J. Methods Enzymol., 271:351-377 (1996)) confirmedformation of fragments that were the size of Fab′.

Formulation pH and protein concentration: The effect of pH on theconformation of rhuMAb CD18 was investigated using fluorescencespectroscopy (FIG. 17). The protein appeared to lose tertiary structurebelow pH 3, but is unchanged in the range of pH 3 to 8.

Based on the above observation, the effect of pH and proteinconcentration on the stability of rhuMAb CD18 was then investigatedusing a central composite design protocol. Formulations containing 10 mMNa citrate, 8% trehalose, 0.05% TWEEN 20™ containing one of thefollowing conditions were prepared: 0.5 mg/mL (pH 4.5), 5 mg/mL (pH 3,4.5, 6), 10 mg/mL (pH 4, 5), 25 mg/mL (pH 4.5). Samples were placed at40° C. and −70° C., and analyzed after 2 month by IEX (FIG. 18A) and SEC(FIG. 18B). Again, pH 5 was found to be the most stable condition forthe protein, irrespective of protein concentration.

Long Term Stability of rhuMAb CD18 Formulation: To address the long termstability of the F2 formulation, duplicate samples in 10 mM Na acetate,8% trehalose, 0.01% TWEEN 20™, pH 5 were prepared in 3 cc glass vialsand placed on stability at the indicated temperatures. Analysis by SEC(FIG. 19A) and MAC-1 binding (FIG. 19C) indicates no change in the sizedistribution, aggregation state, or bioactivity of the protein for up to43 weeks at 5° C; stability up to ˜1 mo at 30° C. is indicated. IEXshows formation of acidic peaks (˜1% after 43 weeks) that wereidentified to be deamidation by peptde mapping/MS (FIG. 19B).

CONCLUSIONS

Preliminary data suggested that the primary reaction in the purifiedrhuMAb CD18 was cleavage to species approximately half the MW of thestarting material, and that this reaction, as well as generation ofacidic peaks on IEX and earlier eluting peaks on HIC and RP-HPLC, wereall minimized at pH 5 (compared to pH 6), and in trehalose (compared tosalt or mannitol). The smaller MW species may have been formed either byproteolytic cleavage and/or by disulfide scrambling, both of which maybe enhanced at higher pH's. Reduction of the control and degradedsamples led to only the light and heavy chains, consistent with eitherthe cleavage to Fab, or mixed disulfide formation between heavy andlight chains.

RhuMAb CD18 appeared to be least stable in salt formulations; at pH 5 alarger aggregate (equivalent to a trimer) appeared and at pH 6precipitation was noted at 40° C. Without being bound to any one theory,one possible explanation is that NaCl does not provide hydrogen bonding,as sugars and mannitol do, which could potentially preventself-association of this antibody at higher temperatures.

Based on the above preliminary data from the primary assays (IEX, SEC,and UV), the preferred aqueous formulation for rhuMAb CD18 is 10 mMsodium acetate, 8% trehalose wN, 0.01% TWEEN 20™, pH 5.0. The shelf-lifepredicted from an Arrhenius fit to the first order rate constants (IEXdata) is 1.7 to 4 years at 5° C. (95% confidence intervals).Thisformulation can be prepared by mixing 0.573 mL glacial acetic acid,0.403 mL concentration NaOH, 80 g trehalose, 1 mL of a 10% TWEEN 20™solution and making up to 1 L with MilliQ water (pH 5.0±0.1 at the 2 Lscale). Conductivity of this formulation was found to be 502±10%microSiemens/cm using a Radiometer-Copenhagen CDM-83 with a CDC 314probe, and density was 1.017 g/mL.

EXAMPLE 2

This example describes the production of a stable aqueous multdoseformulation comprising a recombinant humanized anti-CD20 antibody,rhuMAb CD20. Acetate (pH 5) formulations stored at 40° C. for one monthdemonstrated greater stability than those samples formulated inhistidine (pH 5 or 6). The histidine formulations after acceleratedtemperature storage became very opalescent and yellow in color. Abuffering capacity of 10-30 mM acetate was sufficient to maintain the pHat 5.0. The effective amount of tonicity modifier needed to stabilizethe antibody against freeze or thermal induced aggregation was comparedusing sodium chloride (NaCl) or trehalose. Trehalose was found toprotect the formulation from freeze induced aggregation, particularly atlevels >134 mM (500:1 molar ratio). The trehalose formulations (67-270mM) were much more effective than NaCl in stabilizing formulationsplaced at 40° C. as evidenced by the clarity of the solution. Theseresults led to the development of a stable prototype liquid multidoseformulation comprising 40 mg/mL rhuMAb CD20, 25 mM acetate, 150 mMtrehalose, 0.9% benzyl alcohol, 0.02% polysorbate 20 at pH 5.0 that hasa minimum shelf life of two years storage at 2-8° C.

MATERIALS AND METHODS

RhuMAb CD20: The bulk material used in all studies was composed of 27mg/mL rhuMAb CD20 in 50 mM Tris and 100 mM sodium chloride at pH 7.5 or2.7 mg/mL rhuMAb CD20 in 25 mM Tris and 50 mM sodium chloride at pH 6.0.The bulk was stored aseptically at 2-8° C. in the absence of light.

Buffer exchange: The exchange of the bulk rhuMAb CD20 into differenttest buffers was done by dialysis at 2-8° C. using Spectra/Por® 7membranes (MWCO=8 Kda) which were rinsed thoroughly with deionized waterbefore use. One volume of antibody was dialyzed against a minimum of 10volumes of the appropriate test buffer. This process was repeated threeto four times within a one day period. To obtain the final concentrationof 40 mg/mL, the antibody was further concentrated using an Amicon UF/DFcell containing a YM30 membrane (MWCO=30 KDa). Due to the lower startingconcentration of the 2.7 mg/mL material, this material was firstconcentrated to ˜40 mg/mL and then dialyzed against the appropriate testbuffer. After the target concentration was reached and the bufferexchange completed, trehalose, benzyl alcohol and polysorbate 20 wereadded to the final concentrations described in Tables 15 to 17 below.The liquid multdose C2B8 candidate formulation was 40 mg/mL rhuMAb CD20formulated in 25 mM acetate, 150 mM trehalose, 0.9% benzyl alcohol and0.02% polysorbate 20 at pH 5.0. The formulation was then sterilefiltered through a 0.2μ membrane and the concentration was determined byUV spectrophotometric scan. A 0.5 ml of each final formulation was thenfilled into sterile 3 cc glass vials, stoppered with teflon faced greybutyl rubber stoppers and then capped with crimp seals.

TABLE 15 pH and buffer species comparison study Concentration ofConcentration rhuMAb CD20 of buffer Storage Temperature (mg/mL) species(mM) pH (° C.) 40 50 mM Acetate 5.0 2-8, 40, 50 40 50 mM Histidine 5.02-8, 40, 50 40 50 mM Histidine 6.0 2-8, 40, 50 All formulations contain150 mM trehalose, 0.9% benzyl alcohol and 0.02% polysorbate 20.

TABLE 16 Acetate buffering capacity study Concentration of rhuMAb CD20(mg/mL) mM Acetate Storage temperature (° C.) 40 10 2-8, 40 40 15 2-8,40 40 20 2-8, 40 40 25 2-8, 40 40 30 2-8, 40 All formulations contain150 mM trehalose, 0.9% benzyl alcohol and 0.02% polysorbate 20 at pH5.0.

TABLE 17 Effective ratio of tonicity modifier: rhuMAb CD20 study Molarratio of mM trehalose or sodium Tonicity modifier sugar/salt:rhuMAb CD20chloride Trehalose 0 0 Trehalose 250:1 67 Trehalose 500:1 134 Trehalose1000:1  267 Sodium Chloride 500:1 134 Sodium Chloride 1000:1  267 A).All formulations contained 40 mg/mL rhuMAb CD20, 20 mM acetate, 0.9%benzyl alcohol and 0.02% polysorbate 20 at pH 5.0. B). A freeze-thawcomparison study was completed for the trehalose formulations. Thestability of all formulations at 2-8° and 40° C. was conducted inparallel.

SEC HPLC: Samples were diluted to 10 mg/mL with formulation bufferbefore being assayed. The method uses a TSK G3000 SWXL column (TosoHaas)with a mobile phase consisting of 0.2M potassium phosphate, 0.25Mpotassium chloride, pH.7. The socratic flow rate is 0.5 mLlmin with atotal run time of 30 minutes. The amount of protein injected is 200 μpand the UV absorbance at 280 nm is used as the mode of detection.

HIC HPLC: Samples were diluted to 10 mg/mL with formulation bufferbefore being assayed. The antibody was digested with carboxypeptidaseand papain prior to analysis of the final fragments. The method uses aTSK-GEL butyl-NPR (4.6×35 mm) column. The temperature of the column iscontrolled at 35° C. during the assay. Elution of the antibody fragmentsis induced by changes in the ammonium sulfate gradient. The total runtime of the assay is forty minutes and the flow rate is 1 ml/min. Aprotein load of 5-10 μg is injected and the detection is monitored by UVabsorbance at 214 nm.

UV spectrophotometric scan: For protein concentration determination,samples were accurately diluted 1:100 with formulation buffer. Theabsorbance at 280, 320 and 350 were read with an Hewlett Packard 8451Adiode array spectrophotometer against the same formulation buffer asblank. The protein concentration was calculated by subtracting A₃₂₀ fromA₂₈₀ and dividing by an extinction coefficient of 1.7.

For turbidity evaluaton, samples were scanned without dilution on anHewlett Packard 8451A diode array spectrophotometer and the averageabsorbance in the range of 340-360 nm was determined. Water was used asthe blank.

Accelerated stability studies: The vials were stored upright intemperature-controlled rooms or incubators at 2-8°, 30°, 40° or 50° C.Two to three vials were removed at finite times and the proteindegradation monitored by the stability indicating assays (SEC HPLC, HICHPLC, UV spectrophotometric scan to determine protein concentration andturbidity, as well as pH measurement). In addition, samples weresubjected to the complement dependent cell cytotoxicity assay asdescribed below to assess bioactvity.

Freeze-thaw studies: Samples were exposed to a minimum of two hours offreezing at −70° C. followed by a room temperature thaw (<45 minutes).Each cycle was composed of one freeze followed by one thaw excursion.Three vials were removed per formulation after one, three and fiveconsecutive freeze-thaw cycles and the stability monitored by SEC HPLCand UV spectrophotometric scan to measure the turbidity and proteinconcentration.

Complemnent Dependent Cytotoxicity Assay (CDC): The bioactivity of thestability samples was determined by the CDC assay described in GazzanoSantoro et al., J. Immunol. Meth. 202:163-171 (1997), except that humancomplement (rather than rabbit complement) was used. The percentbioactvity of the test sample was determined as follows,$\text{\%~~bioactivity} = {\frac{\begin{matrix}\left\lbrack \left( {{CDC}\quad {assay}\quad {{mg}/{mL}}\quad {of}\quad {{sample}/}} \right. \right. \\\left. \left. {{protein}\quad {concentration}\quad {of}\quad {sample}} \right) \right\rbrack\end{matrix}}{\begin{matrix}\left\lbrack \left( {{CDC}\quad {assay}\quad {{mg}/{mL}}\quad {of}\quad {{reference}/}} \right. \right. \\\left. \left. {{protein}\quad {concentration}\quad {reference}} \right) \right\rbrack\end{matrix}} \times 100}$

The protein concentration of the test sample and reference control weredetermined by UV spectrophotometric scan.

RESULTS AND DISCUSSION

pH and buffer species: Decreasing the pH from 7.5 to 5.0 of 40 mg/mLrhuMAb CD20 formulated in histidine and trehalose virtually eliminatedoxidation of the antibody even after two months storage at 40° C. (FIG.24B). There is also a decline in the rate of aggregation but thedifference below pH 6.5 is slight (FIG. 24A). Further reduction inaggregation rate may require a decrease in the protein concentration. Astable formulation appears to require a pH in the acidic range.

To differentate between the effect of buffer species and the effect ofpH, histidine (5 or 6) and acetate (5), multdose formulations werecompared after storage at 2-8°, 40° or 50° C. The samples were stored at50° C. as a way of quickly determining the relative stability betweenthe formulations with the caveat that the degradation observed was notnecessarily predictive of that seen at 2-8° C. storage.

The visual clarity of the formulations and the turbidity as measured byUV spectrophotometric scan (340-360 nm) after four (50° C.) and eight(2-8°, 40° C.) weeks storage is described in Tab Both histidineformulations were more opalescent than the acetate at all temperaturesstudied. After two weeks storage at 50° C., the histdine at pH 5 hadformed a solid opaque gel while the sibling formulation at pH 6 wasvisually cloudy and yellow in color by four weeks. The histidineformulations stored at 40° C. also turned yellow. Without being bound toany one theory, the color formation is likely due to the oxidation ofhistidine and is more apparent in this study due to the highconcentration of histidine used (50 mM). No differences were observed at2-8° C. storage relative to the initial timepoint.

TABLE 18 The effect of buffer species and pH on the appearance andclarity of 40 mg/mL rhuMAb CD20 multidose formulations containing 50 mMacetate or histidine, 150 mM trehalose, 0.9% benzyl alcohol and 0.02%polysorbate 20 at pH 5 or 6. Turbidity Avg. O.D. Formulation TemperatureAppearance 340-360 nm T = 8 weeks Acetate pH 5 Clear 0.051 ± 0.001 Histidine pH 5 2-8° C. Clear 0.065 ± 0.0002 Histidine pH 6 Clear 0.068 ±0.001  Acetate pH 5 40° C. Opalescent 0.16 ± 0.002 Histidine pH 5 40° C.Light yellow, 0.28 ± 0.015 Opalescent Histidine pH 6 40° C. Lightyellow, 0.36 ± 0.026 Opalescent T = 4 weeks Acetate pH 5 50° C. VeryOpalescent 0.61 ± 0.007 Histidine pH 5 50° C. Firm opaque gel N/D¹Histidine pH 6 50° C. Cloudy, yellow solution 1.30 ± 0.20  ¹Theturbidity was not determined (N/D) due to the gelation of the sample.

The stability was also monitored by HIC and SEC HPLC methods. Aftereight weeks storage at 40° C., the acetate pH 5 formulations wereunchanged while the histidine pH 6 formulations had a 18 percentreduction in unoxidized Fc relative to the initial bmepoint (Table 19).The percentage monomer decreased in all formulations stored at 40° C.with the histidine pH 6 being slightly more stable. This reduction wasattributed to the formation of a high molecular weight aggregate(s)eluting at the void volume, a lagging shoulder on the monomer peak andlower molecular weight species. The protein concentration and pH werealso measured, except in the case of gelation, and no changes wereobserved over the duration of the study.

TABLE 19 The effect of buffer species and pH on the percentageunoxidized Fc and percentage monomer of 40 mg/mL rhuMAb CD20 multidoseformulations containing 50 mM acetate or histidine, 150 mM trehalose,0.9% benzyl alcohol and 0.02% polysorbate 20 at pH 5 or 6. % UnoxidizedFc % Monomer Formulation Temperature (HIC HPLC) (SEC HPLC) T = 0 AcetatepH 5 2-8° C. 93.9 99.4 Histidine pH 5 2-8° C. 99.1 99.4 Histidine pH62-8° C. 99.3 98.5 T = 8 weeks Acetate pH 5 40° C. 96.5 90.4 Histidine pH5 40° C. 87.0 87.4 Histidine pH 6 40° C. 81.7 93.9

Since the acetate pH 5 formulation had only a slightly higheraggregation rate, did not turn yellow upon storage at high temperaturesand had the greatest clarity under all conditions studied, it was chosenas the buffer species and pH of choice for all subsequent liquid C2B8multidose formulation screens.

Amount of buffering species: The amount of acetate which maintained thepH of a 40 mg/mL C2B8 multidose formulation at 5.0 was determined.Summarized in Table 20 is the effect on pH as the acetate bufferconcentration was increased from 10 to 30 mM. At two and four weeksthere appeared to be a slight advantage in staying above 15 mM acetate,although this did not hold true upon long term storage. No change wasseen in the pH in any of the test formulations studied after one yearsstorage at 2-8° C. A range of 10 to 30 mM acetate is sufficient tomaintain the pH at 5.0.

TABLE 20 The effect of acetate buffer concentration on maintaining thepH of liquid rhuMAb CD20 multidose formulations at 5.0. The formulationswere composed of 40 mg/mL rhuMAb CD20, 10 to 30 mM acetate, 150 mMtrehalose, 0.9% benzyl alcohol, 0.02% polysorbate 20 at pH 5.0. mM pH(weeks) Acetate 0 2 4 56 2-8° C. 10 5.03 5.12 5.11 5.00 15 5.07 5.125.14 5.06 20 5.04 5.04 5.04 5.00 25 5.01 5.00 5.02 4.98 30 5.01 5.005.02 4.98 40° C. 10 5.12 5.14 15 5.10 5.17 20 5.08 5.10 25 5.05 5.05 305.03 5.05

Ratio of tonicity modifier: protein: The addition of trehalose wasbeneficial to the stability of rhuMAb CD20 multdose formulations aftermultiple freeze/thaw cycles (FIG. 25). A decrease in the formation ofsoluble aggregates was observed as the concentration of trehalose in theformulation was increased. At a ratio of 500 moles trehalose:1 mole C2B8(134 mM trehalose), the percentage of aggregate formed was only 0.5%after five freeze-thaw cycles while the control formulation containingno isotonicity modifier formed 4% aggregate. Having at least a 500 foldmolar excess of trehalose in the liquid C2B8 formulation offeredsufficient protection against freeze induced aggregation.

The ability of trehalose to stabilize rhuMAb CD20 during acceleratedtemperature storage was studied and compared to sodium chloride.

FIG. 26 describes the effect of excess molar ratios of trehalose orsodium chloride on the clarity of test formulations stored at 40° C.Sodium chloride is deleterious to the stability. After two weeks storageat 40° C., the 500:1 ratio sample had an O.D. of 0.44. At a 1000:1 molarratio, the sodium chloride containing formulation separated into a twophase system composed of an opaque gel covered with an opalescent fluidon top. In contrast, there was little change in the solution clarity ofthe samples containing 0 to 1000:1 molar ratio of trehalose even afterone months storage at 40° C. Although the 2-8° C. formulations wereunchanged from the initial bmepoint, the sodium chloride containingsamples were more opalescent.

The effect of trehalose on minimizing the soluble aggregate formationwas assessed by SEC HPLC (FIG. 27). No differences were observed betweenthe trehalose formulations and the negative control which contained notonicity modifier. The formulations appeared to degrade at the same rateto the same products upon storage at 40° C. The pH and concentrationwere also maintained over the duration of the study .

The presence of trehalose is beneficial in minimizing freeze-inducedaggregation and is not deleterious to the stability in the liquid state.The candidate liquid multidose formulation preferably contains at least500:1 molar ratio of trehalose to C2B8.

Stability of candidate liquid multidose formulation: Based on theaforementioned studies, a protoype liquid multidose formulation composedof 40 mg/mL rhuMAb CD20, 25 mM acetate, 150 mM trehalose, 0.9% benzylalcohol and 0.02% polysorbate 20 at pH 5.0 was placed on stability at2-8°, 30° C. and 40° C. The stability profile by SEC HPLC at eachtemperature studied is shown in FIG. 28. Although the rate ofaggregation is slightly faster at 40° C. for the multidose formulation(40 mg/mL) compared to the reference control (10 mg/mL rhuMAb CD20, 25mM citrate, 150 mM sodium chloride, 0.07% polysorbate 80 at pH 6.5), nodecrease in percentage monomer was observed upon storage at 2-8° C. fortwo years. The bioactivity of the two year old 2-8° C. samples was 99.2%relative to the reference control as determined by the CDC assay.

CONCLUSIONS

The above screening studies indicated that a stable high concentrationrhuMAb CD20 liquid multidose formulation was possible by buffering withacetate, maintaining the pH at 5 and including preferably at least about500 moles of trehalose per mole of antibody. The preferred liquidmultidose configuration is composed of 40 mg/mL rhuMAb CD20, 25 mMacetate, 150 mM trehalose, 0.9% benzyl alcohol and 0.02% polysorbate 20at pH 5 and has a shelf life of two years at 2-8° C.

11 241 amino acids Amino Acid Linear unknown 1 Glu Val Gln Leu Val GluSer Gly Gly Gly Leu Val Gln Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu SerCys Ala Thr Ser Gly Tyr Thr Phe Thr 20 25 30 Glu Tyr Thr Met His Trp MetArg Gln Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ala Gly Ile Asn ProLys Asn Gly Gly Thr Ser His 50 55 60 Asn Gln Arg Phe Met Asp Arg Phe ThrIle Ser Val Asp Lys Ser 65 70 75 Thr Ser Thr Ala Tyr Met Gln Met Asn SerLeu Arg Ala Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ala Arg Trp Arg GlyLeu Asn Tyr Gly 95 100 105 Phe Asp Val Arg Tyr Phe Asp Val Trp Gly GlnGly Thr Leu Val 110 115 120 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro SerVal Phe Pro Leu 125 130 135 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly ThrAla Ala Leu Gly 140 145 150 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro ValThr Val Ser Trp 155 160 165 Asn Ser Gly Ala Leu Thr Ser Gly Val His ThrPhe Pro Ala Val 170 175 180 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser SerVal Val Thr Val 185 190 195 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr IleCys Asn Val Asn 200 205 210 His Lys Pro Ser Asn Thr Lys Val Asp Lys LysVal Glu Pro Lys 215 220 225 Ser Cys Asp Lys Thr His Thr Cys Pro Pro CysPro Ala Pro Glu 230 235 240 Leu 241 214 amino acids Amino Acid Linearunknown 2 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val 15 10 15 Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Asn 2025 30 Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys 35 4045 Leu Leu Ile Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser 50 55 60Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile 65 70 75 SerSer Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln 80 85 90 Gly AsnThr Leu Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu 95 100 105 Ile LysArg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 110 115 120 Ser AspGlu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 125 130 135 Leu AsnAsn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val 140 145 150 Asp AsnAla Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu 155 160 165 Gln AspSer Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 170 175 180 Leu SerLys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 185 190 195 Val ThrHis Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 200 205 210 Arg GlyGlu Cys 214 36 amino acids Amino Acid Linear unknown 3 Leu Gly Gly ArgMet Lys Gln Leu Glu Asp Lys Val Glu Glu Leu 1 5 10 15 Leu Ser Lys AsnTyr His Leu Glu Asn Glu Val Ala Arg Leu Lys 20 25 30 Lys Leu Val Gly GluArg 35 36 11 amino acids Amino Acid Linear unknown 4 Pro Lys Asn Ser SerMet Ile Ser Asn Thr Pro 1 5 10 11 7 amino acids Amino Acid Linearunknown 5 His Gln Ser Leu Gly Thr Gln 1 5 7 8 amino acids Amino AcidLinear unknown 6 His Gln Asn Leu Ser Asp Gly Lys 1 5 8 8 amino acidsAmino Acid Linear unknown 7 His Gln Asn Ile Ser Asp Gly Lys 1 5 8 8amino acids Amino Acid Linear unknown 8 Val Ile Ser Ser His Leu Gly Gln1 5 8 2143 base pairs Nucleic Acid Single Linear unknown 9 GAATTCAACTTCTCCATACT TTGGATAAGG AAATACAGAC ATGAAAAATC 50 TCATTGCTGA GTTGTTATTTAAGCTTTGGA GATTATCGTC ACTGCAATGC 100 TTCGCAATAT GGCGCAAAAT GACCAACAGCGGTTGATTGA TCAGGTAGAG 150 GGGGCGCTGT ACGAGGTAAA GCCCGATGCC AGCATTCCTGACGACGATAC 200 GGAGCTGCTG CGCGATTACG TAAAGAAGTT ATTGAAGCAT CCTCGTCAGT250 AAAAAGTTAA TCTTTTCAAC AGCTGTCATA AAGTTGTCAC GGCCGAGACT 300TATAGTCGCT TTGTTTTTAT TTTTTAATGT ATTTGTAACT AGAATTCGAG 350 CTCGCCGGGGATCCTCTAGA GGTTGAGGTG ATTTTATGAA AAAGAATATC 400 GCATTTCTTC TTGCATCTATGTTCGTTTTT TCTATTGCTA CAAACGCGTA 450 CGCTGATATC CAGATGACCC AGTCCCCGAGCTCCCTGTCC GCCTCTGTGG 500 GCGATAGGGT CACCATCACC TGTCGTGCCA GTCAGGACATCAACAATTAT 550 CTGAACTGGT ATCAACAGAA ACCAGGAAAA GCTCCGAAAC TACTGATTTA600 CTATACCTCC ACCCTCCACT CTGGAGTCCC TTCTCGCTTC TCTGGTTCTG 650GTTCTGGGAC GGATTACACT CTGACCATCA GCAGTCTGCA ACCGGAGGAC 700 TTCGCAACTTATTACTGTCA GCAAGGTAAT ACTCTGCCGC CGACGTTCGG 750 ACAGGGCACG AAGGTGGAGATCAAACGAAC TGTGGCTGCA CCATCTGTCT 800 TCATCTTCCC GCCATCTGAT GAGCAGTTGAAATCTGGAAC TGCCTCTGTT 850 GTGTGCCTGC TGAATAACTT CTATCCCAGA GAGGCCAAAGTACAGTGGAA 900 GGTGGATAAC GCCCTCCAAT CGGGTAACTC CCAGGAGAGT GTCACAGAGC950 AGGACAGCAA GGACAGCACC TACAGCCTCA GCAGCACCCT GACGCTGAGC 1000AAAGCAGACT ACGAGAAACA CAAAGTCTAC GCCTGCGAAG TCACCCATCA 1050 GGGCCTGAGCTCGCCCGTCA CAAAGAGCTT CAACAGGGGA GAGTGTTAAG 1100 CTGATCCTCT ACGCCGGACGCATCGTGGCG CTAGTACGCA AGTTCACGTA 1150 AAAACGGTAT CTAGAGGTTG AGGTGATTTTATGAAAAAGA ATATCGCATT 1200 TCTTCTTGCA TCTATGTTCG TTTTTTCTAT TGCTACAAACGCGTACGCTG 1250 AGGTTCAGCT GGTGGAGTCT GGCGGTGGCC TGGTGCAGCC AGGGGGCTCA1300 CTCCGTTTGT CCTGTGCAAC TTCTGGCTAC ACCTTTACCG AATACACTAT 1350GCACTGGATG CGTCAGGCCC CGGGTAAGGG CCTGGAATGG GTTGCAGGGA 1400 TTAATCCTAAAAACGGTGGT ACCAGCCACA ACCAGAGGTT CATGGACCGT 1450 TTCACTATAA GCGTAGATAAATCCACCAGT ACAGCCTACA TGCAAATGAA 1500 CAGCCTGCGT GCTGAGGACA CTGCCGTCTATTATTGTGCT AGATGGCGAG 1550 GCCTGAACTA CGGCTTTGAC GTCCGTTATT TTGACGTCTGGGGTCAAGGA 1600 ACCCTGGTCA CCGTCTCCTC GGCCTCCACC AAGGGCCCAT CGGTCTTCCC1650 CCTGGCACCC TCCTCCAAGA GCACCTCTGG GGGCACAGCG GCCCTGGGCT 1700GCCTGGTCAA GGACTACTTC CCCGAACCGG TGACGGTGTC GTGGAACTCA 1750 GGCGCCCTGACCAGCGGCGT GCACACCTTC CCGGCTGTCC TACAGTCCTC 1800 AGGACTCTAC TCCCTCAGCAGCGTGGTGAC CGTGCCCTCC AGCAGCTTGG 1850 GCACCCAGAC CTACATCTGC AACGTGAATCACAAGCCCAG CAACACCAAG 1900 GTCGACAAGA AAGTTGAGCC CAAATCTTGT GACAAAACTCACACATGCCC 1950 GCCGTGCCCA GCACCAGAAC TGCTGGGCGG CCGCATGAAA CAGCTAGAGG2000 ACAAGGTCGA AGAGCTACTC TCCAAGAACT ACCACCTAGA GAATGAAGTG 2050GCAAGACTCA AAAAGCTTGT CGGGGAGCGC TAAGCATGCG ACGGCCCTAG 2100 AGTCCCTAACGCTCGGTTGC CGCCGGGCGT TTTTTATTGT TAA 2143 237 amino acids Amino AcidLinear unknown 10 Met Lys Lys Asn Ile Ala Phe Leu Leu Ala Ser Met PheVal Phe -23 -20 -15 -10 Ser Ile Ala Thr Asn Ala Tyr Ala Asp Ile Gln MetThr Gln Ser -5 1 5 Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val ThrIle Thr 10 15 20 Cys Arg Ala Ser Gln Asp Ile Asn Asn Tyr Leu Asn Trp TyrGln 25 30 35 Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Tyr Thr Ser40 45 50 Thr Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser 5560 65 Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp 70 7580 Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Pro Thr 85 90 95Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 115 120 125Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 145 150 155Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 160 165 170Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 175 180 185Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 190 195 200Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 205 210 214 300 aminoacids Amino Acid Linear unknown 11 Met Lys Lys Asn Ile Ala Phe Leu LeuAla Ser Met Phe Val Phe -23 -20 -15 -10 Ser Ile Ala Thr Asn Ala Tyr AlaGlu Val Gln Leu Val Glu Ser -5 1 5 Gly Gly Gly Leu Val Gln Pro Gly GlySer Leu Arg Leu Ser Cys 10 15 20 Ala Thr Ser Gly Tyr Thr Phe Thr Glu TyrThr Met His Trp Met 25 30 35 Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp ValAla Gly Ile Asn 40 45 50 Pro Lys Asn Gly Gly Thr Ser His Asn Gln Arg PheMet Asp Arg 55 60 65 Phe Thr Ile Ser Val Asp Lys Ser Thr Ser Thr Ala TyrMet Gln 70 75 80 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr CysAla 85 90 95 Arg Trp Arg Gly Leu Asn Tyr Gly Phe Asp Val Arg Tyr Phe Asp100 105 110 Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr115 120 125 Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr130 135 140 Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145 150 155 Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser160 165 170 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr175 180 185 Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr190 195 200 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys205 210 215 Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr220 225 230 Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Arg Met Lys235 240 245 Gln Leu Glu Asp Lys Val Glu Glu Leu Leu Ser Lys Asn Tyr His250 255 260 Leu Glu Asn Glu Val Ala Arg Leu Lys Lys Leu Val Gly Glu Arg265 270 275 277

What is claimed is:
 1. A stable aqueous pharmaceutical formulationcomprising a therapeutically effective amount of an antibody notsubjected to prior lyophilization, an acetate buffer from about pH 4.8to about 5.5, a surfactant and a polyol, wherein the formulation lacks atonicifying amount of sodium chloride.
 2. The formulation of claim 1which is isotonic.
 3. The formulation of claim 1 which is stable at atemperature of about 2-8° C. for at least one year.
 4. The formulationof claim 1 which is stable following freezing and thawing of theformulation.
 5. The formulation of claim 1 which is stable at about 30°C. for at least one month.
 6. The formulation of claim 1 wherein thepolyol is a nonreducing sugar.
 7. The formulation of claim 6 wherein thenonreducing sugar is trehalose.
 8. The formulation of claim 6 whereinthe nonreducing sugar is sucrose.
 9. The formulation of claim 1 whereinthe antibody is an antibody fragment.
 10. The formulation of claim 9wherein the antibody fragment is a F(ab′)₂.
 11. The formulation of claim1 wherein the antibody binds CD18.
 12. The formulation of claim 1 whichis stable at a temperature of about 2-8° C. for at least two years. 13.The formulation of claim 1 wherein the antibody concentration in theformulation is from about 0.1 to about 50 mg/mL.
 14. The formulation ofclaim 1 wherein the surfactant is a polysorbate.
 15. The formulation ofclaim 1 wherein the antibody binds CD20.
 16. The formulation of claim 15wherein the acetate is present in an amount of about 5-30 mM.
 17. Theformulation of claim 16 wherein the acetate is present in an amount of10-30 mM.
 18. The formulation of claim 15 further comprising apreservative.
 19. The formulation of claim 18 wherein the preservativeis benzyl alcohol.
 20. The formulation of claim 15 wherein the antibodyis present in an amount of about 30-50 mg/mL.
 21. The formulation ofclaim 20 wherein the buffer is 10-30 mM sodium acetate at pH 5, thepolyol is trehalose in an amount of about 2-10% w/v, the surfactant ispolysorbate in an amount of about 0.01-0.1% v/v, wherein the formulationfurther comprises benzyl alcohol as a preservative and wherein theformulation is stable at a temperature of about 2-8° C. for at least twoyears.
 22. An article of manufacture comprising a container holding astable aqueous pharmaceutical formulation comprising a therapeuticallyeffective amount of an antibody not subjected to prior lyophilization,an acetate buffer from about pH 4.8 to about 5.5, a surfactant and apolyol, wherein the formulation lacks a tonicifying amount of sodiumchloride.
 23. A method for stabilizing an antibody in an aqueouspharmaceutical formulation by combining a therapeutically effectiveamount of an antibody not subjected to prior lyophilization, an acetatebuffer from about pH 4.8 to about 5.5, a surfactant and a polyol,wherein the formulation lacks a tonicifying amount of sodium chloride.24. A stable aqueous pharmaceutical formulation comprising atherapeutically effective amount of an antibody not subjected to priorlyophilization, a 10-30 mM acetate buffer at pH 5.0, a surfactant, andtrehalose at a concentration of at least 134 mM, wherein the formulationlacks a tonicifying amount of sodium chloride.
 25. The formulation ofclaim 24 wherein the antibody binds CD18 or CD20.
 26. The formulation ofclaim 25 wherein the CD18 binding antibody is a F(ab′)₂ fragment.
 27. Anarticle of manufacture comprising a container holding the formulation ofclaim
 25. 28. The formulation of claim 1, wherein the acetate buffer isat pH 5.0.
 29. The formulation of claim 28, wherein the antibody bindsCD20.